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ABSTRACT 
 
GENE DELIVERY TO THE BLOOD BRAIN BARRIER FOR STROKE THERAPY 
 
 
 
 
By 
Wanzhu Zhao 
May 2020 
 
Thesis supervised by Devika Soundara Manickam 
Stroke is a major cause of death in the United States. Only one food and drug 
administration (FDA) approved drug, tissue plasminogen activator (tPA), is available for 
the treatment of stroke. However, due to limited number of patients who can benefit from 
tPA, it is urgent to develop a novel therapy to decrease patient death and disability. Thus, 
we aim to develop safe and efficient approaches for the treatment of stroke. Regenerative 
therapies have been  identified as the major need for curing stroke [1]. We explored two 
different carriers (poly (ethylene glycol)5k-poly (L-aspartate-diethylenetriamine)48 (PEG-
DET) / Pluronic P84 (P84) and exosomes (EXOs) / microvesicles (MVs)) to deliver brain-
derived neurotrophic factor (BDNF) plasmid DNA (pDNA), a functional gene encoding a 
neurotrophin. In the first project, our data showed that DNA nanoparticles (NPs) with 
0.03% P84 was a promising formulation to deliver Luciferase pDNA into immortalized 
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human cerebral microvascular endothelial cells (hCMEC/D3 cells) efficiently. In order to 
investigate the cytotoxicity of the formulation in the integrity of tight junctions (TJs), a 
lucifer yellow apparent permeability (LY Papp) method was developed to determine that 
DNA NPs with 0.03% P84 was a safe formulation for TJ integrity. However, this 
formulation did not result in increased BDNF secretion compared to untreated cells. To 
determine if natural carriers such as extracellular vesicles can deliver BDNF pDNA into 
hCMEC/D3 cells, we isolated EXOs and MVs from the hCMEC/D3 cell line. We used a 
standard differential ultracentrifugation method to extract EXOs and MVs from 
supernatant of hCMEC/D3 cell medium and characterized EXOs and MVs by particle size 
measurement and western blotting. However, the transfection efficiency of extracellular 
vesicles (EVs) was low. Remarkably, we found that plain EXOs and MVs at a certain EV 
protein level (6 µg) resulted in relatively higher cellular ATP levels in health cells, which 
indicated that EXOs and MVs had a great potential to provide extra nutrients and energy 
for injured cells. 
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Chapter 1: Introduction 
 
 
1.1. The structure, role and function of the BBB 
 
The blood-brain barrier (BBB) lines the capillaries surrounding the brain tissue and is formed by 
cerebral endothelial cells, the choroid plexus epithelial cells and the cells of the arachnoid 
epithelium [2]. The main role of BBB is to maintain homeostasis of the neural microenvironment. 
The BBB provides a physical barrier to seal the space between peripheral blood and central 
nervous system (CNS), limit the paracellular diffusion, also serves as ion regulator and metabolic 
barrier to modulate ion permeability and prevent many macromolecules from entering the brain 
[2-5].  
 
Adherens junctions (AJs) and tight junction (TJs) are essential junctional complexes between 
endothelial cells. The AJs provide force for cell-cell adhesion via the scaffolding proteins alpha, 
beta and gamma catenin.  The tight junctions, such as zonulae occludentens (ZO-1, ZO-2, ZO-3), 
act as a fence by hindering the movement of ions and macromolecules between  the apical (blood-
facing) and basolateral compartments (brain-facing) [6]. In addition, many efflux transporters are 
involved in the formation of BBB to pump a wide range of hydrophobic compounds out of the 
brain endothelium, such as P-glycoprotein (Pgp) [2, 7, 8].  This is the main reason that a significant 
number of drugs with lipophilic structures have a much lower CNS permeability than predicted 
from their logD [8]. Although BBB prevents many molecules from entering the brain, specific 
transport systems are expressed in the BBB to carry molecules and complexes across the BBB for 
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adequate supply of brain nutrition. For essential polar nutrients such as glucose and amino acids, 
specialized solute carriers such as glucose transporter 1 (GLUT1) and large neutral amino acid 
transporters (LAT1) is used for transport from blood to the brain [9]. For delivery of 
macromolecules such as polymers and nanoparticles, transcytosis is the main route for 
macromolecule entry through the BBB [2]. In this process, the transcytosis is initiated by 
interaction between specific ligands in the structure of macromolecules and corresponding 
receptors on the surface of brain endothelial cells [2]. The specific ligands for transcytosis include 
transferrin (Tf), insulin, apolipoprotein E (ApoE) and so on, which prompts novel developments 
aiming to potentiate drug delivery to the brain [10]. For example, liposomes coated with Tf showed 
significantly greater brain uptake after i.v. administration in rats compared to the liposomes alone 
[11].  
 
1.2. Neurovascular unit (NVU)  
 
Neurovascular unit (NVU) is defined as a group of cells, including neurons, astrocytes, endothelial 
cells, pericytes, extracellular matrix components, and smooth muscle cells surrounding 
microvessels [12, 13] (Figure 1-1). To accomplish the cerebral demands, two main mechanisms 
are involved in transportation of oxygen and nutrients into the brain, hyperaemia and 
autoregulation. They regulate the brain blood flow to meet the requirement of oxygen and glucose 
in the brain. Autoregulation is the mechanism that maintains the brain blood pressure within the 
range of 50-150 mmHg [14]. Hyperaemia is the mechanism to adjust the local blood flow to fit the 
changes in activity of specific brain sections, such as calculation, mental exercise [15, 16]. Both 
mechanisms, autoregulation and hyperaemia regulate the change of diameter of intraluminal 
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vessels [16]. These changes in the vessels are called as vasodilation (enlarging vessel diameter) 
and vasoconstriction (shrinking vessel diameter) [12, 17], which are regulated by neurovascular 
unit, a group of cells constitutes an integrative biological system to enable proper brain 
homeostasis and functioning [18]. For example, NVU secretes many factors, such as nitric oxide 
(NO), adenosine to induce the contraction and relaxation  of brain vessels, leading to the change 
of blood flow in the brain [19, 20]. The group of cells in NVU share a similar embryonic origin 
and are nourished by the same growth factors, such as vascular endothelial growth factor (VEGF) 
and brain-derived neurotrophic factor (BDNF) [21, 22], but each type of cell in NVU plays a 
specific and active role and communicates with other cells and maintain the dynamic stable of 
microenvironment under physiological conditions [12].  
 
Neurons can sense the subtle change in their microenvironment and release chemical and electrical 
messages to adjacent astrocytes or interneurons [12, 21].  Although the function of astrocytes 
continues to be defined, it is known that astrocytes using their end feet on the capillary abluminal 
to transfer and amplify these chemical and electrical messages initiated from neurons to the 
pericytes and smooth muscle cells of the vessels and pericytes, which results in vasoconstriction 
or vasodilation [12, 23]. Pericytes are embedded within the vascular basement membrane [24] and 
closely interact with endothelial cells [12, 25]. Similarly to astrocytes, the roles of pericyte remains 
largely unknown, but many studies reported that pericytes played a pivotal role in formation and 
regulation of BBB [25-27]. Armulik and coworkers provided evidence that the pericyte-deficient 
mutant mouse showed increased permeability to the drug imatinib in the brain, and they dictated 
that the critical role of pericytes was to regulate BBB-specific gene expressed in endothelial cells 
and maintain the structure of astrocyte end-feet (Figure 1-1) [25]. Like astrocytes and pericytes, 
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the function of cerebral endothelial cells was initially described as simple support cells, forming a 
physical wall to separate the circulating blood from the brain and extracellular fluid in the CNS. 
Recently, specific studies are being reported about the interactions between endothelium and 
neurons promote neurogenesis and angiogenesis [22, 28]. Neurotrophins (NTR) such as BDNF are 
produced by brain endothelial cells to regulate the survival and differentiation of neurons [29, 30]. 
Several studies demonstrated that cerebral endothelial cells provide significant neurotrophic 
influences on neuronal development and neurogenesis [22, 28, 30]. Vascular growth also is 
modulated via the secretion of vascular endothelial growth factor (VEGF) by neuronal precursor 
cells [22, 28]. Above all, BBB serves as a physical guard to maintain the brain homeostasis and 
support normal function of NVU. At the same time, astrocytes, pericytes and neuron cells assist 
the formation of BBB and regulate BBB, such as vasodilation or vasoconstriction, for the needs of 
neuronal supply. Published papers reported that extracellular ATP caused vasoconstriction by 
inducing depolarizing changes in the ionic currents and increased calcium levels [31-34]. ATP 
might also mediate the intercellular signaling [34]. For example,  in the study reported by Schlosser 
and coworkers, the presence of 20 - 200 nM ATP increased florescence-intensity of intercellular 
Ca2+ [Ca2+]i in isolated rat hepatocytes by using confocal fluorescence video microscopy [34]. In 
opposite, some studies demonstrated that the desensitization of the ATP receptor blocked the 
responses of nerve stimulation [35]. Kawamura and coworkers measured the change of pericyte 
currents during the exposure of 100 µM ATP to pericytes in an isolated rat retinal microvessel and 
concluded that the cell-to cell electrotonic transmission was inhibited [31]. One possible reason 
for the two opposite results was the tested concentration ranges of ATP levels were very different: 
one being at nanomolar while another being at the micromolar level. However, owing to technical 
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challenges in the in vivo applications of electrophysiological and imaging methods, there is still 
short of evidence to demonstrate the effects of ATP in cell - to cell communication. 
 
 
Figure 1-1 The figure shows the components of the neurovascular unit: the neuron (purple) 
establishes synapses with astrocyte (magenta), sending information for the requirements and 
commands of contraction or vascular relaxation. Astrocyte contacts endothelial cell (orange), 
pericyte (green) or smooth muscle cells (brown) directly via the end-feet to transmit messages to 
the vessels. 
 
1.3. Pathophysiology of BBB during disease 
 
The barrier function is not static at all times and can be modulated both in physiology and 
pathology. There is a growing list of CNS pathologies that are related to BBB dysfunction. 
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Neurological disease is a collective term that indicates diseases affecting the CNS. As of 2011, 
nearly 100 million Americans suffered at least one of the >1,000 neurological diseases and lost 
productivity due to morbidity and disability [36, 37].  For example, stroke is a major cause of death 
and affects 6.8 million people in the United State in 2013 [38]. On average, someone in the United 
States has a stroke every 40 seconds and someone dies every 4 minutes [36, 38]. Currently, tissue 
plasminogen activator (tPA) is the only clinically approved stroke therapy. Thus, it is urgent to 
develop novel therapies to effectively treat stroke. Although the brain composes only 2.0 - 2.3% 
of the body’s mass, about 20% - 30% of the body’s total energy is consumed by the brain when it 
is awake but unstimulated [39, 40]. Because the brain almost does not store energy and lacks 
anaerobic metabolism, the proper function and activity of brain microvasculature network plays 
the critical role in serving primary cerebral fuel [41, 42]. Without enough energy supply to obtain 
high metabolic demands, these brain neurons cannot function well. Ischemic stroke occurs when 
blood clots suddenly stop the flow of blood into brain tissue, and interrupt the cerebral 
microcirculation in a specific region of brain [18]. The affected brain areas are divided into two 
regions, the core, where the blood flow is highly disrupted and brain tissues die due to necrosis, 
and the penumbra, which surrounds the severely damaged ischemic core and could be salvaged if 
blood flow is restored early [18, 43]. The subsequent oxygen-glucose deprivation initiates 
capspase-8, which subsequently activates the Bcl-2 family member protein Bid [44]. The release 
of Bid results in release of cytoplasm cytochrome c (cyt c) from mitochondria after ischemia [44, 
45]. The loss of cyt c will block the production of ATP and increase formation of reactive oxygen 
species, which potentially leads to necrosis. Simultaneously, the unleashed cyt c will induce 
mitochondrial insult which activates caspase 3 to hydrolysis cytoplasmic protein, leading to 
apoptosis [45, 46]. After ischemic stroke, BBB integrity is compromised as a consequence of the 
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breakdown of cell-cell interactions in the NVU [47]. A wide range of inflammatory molecules and 
xenobiotics crosses the BBB following cerebral reperfusion because of BBB damage [18]. Without 
the protection of BBB, the function of NVU is continuously challenged, even as multiple signaling 
pathways from NVU attempt to counter the stress triggered by ischemic injury. However, these 
rescuing processes are not always successful and may lead NVU loss-of-function, or even prevent 
pharmacotherapies entering brain [48]. For instance, the NVU upregulates the expression of 
multidrug resistance protein-1 to eliminate toxic molecule entering the brain during ischemia. 
However, it also limits the entry of neuroprotective drugs into the ischemic brain [49]. 
 
1.4. Drug delivery to the BBB with a focus of nucleic acids (DNA) 
 
Despite decades of research directed towards developing therapies, it is disappointing to 
acknowledge that there exists only one approved drug (tissue plasminogen activator (tPA)) for the 
treatment of acute stroke that need to be initiated within 3 h of stroke event [50]. The short time 
window only makes 3% to 5% of stroke patients reach a hospital in time for this treatment [51]. 
The tPA is a serine protease to catalyze the conversion of plasminogen to plasmin, which is the 
major enzyme responsible for clot breakdown. Since tPA dissolves blood clots, there is risk of 
hemorrhage with its use, especially for patients who have large blood clots. Approximately 2% - 
6% patients complicates about hemorrhage related to intravenous tPA [52]. Thus, a computed 
tomography (CT) scan is required to reveal the clot’s location and guide the decision regarding 
tPA [53]. Restoration of the blood supply is another valid strategy to reduce infarct size and 
improve clinical outcome in some patients. However, reperfusion may further deteriorate the brain 
injury referred as ischemic reperfusion injury [54, 55]. The influx of leukocytes and accompanying 
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red blood cells during reperfusion may cause capillary obstruction, and prevent the restoration of 
blood flow, resulting in a secondary cerebral ischemia [55]. Therefore, safer and more efficient 
approaches for treatment of ischemia are in high demand. 
 
The concepts of NVU emphasizes the importance of homeostatic interactions between endothelial 
cells and neuronal parenchyma [30]. Endothelial cells (ECs) build blood vessels, and the vascular 
network provides oxygen, glucose, and nutrients for neuronal activities [56]. Conversely, the 
neuronal network regulates the morphology of blood vessels in response to the local conditions 
[57]. Thus, to respond the change of environments, ECs and neuronal cells produce growth factors 
and corresponding receptors. These factors and receptors act as sensors of environment changes 
and transfer information to initiate the proliferation, differentiation of ECs and neuronal cells [57]. 
Thus, there is a great deal of research focusing on these factors and their receptors for angiogenesis 
and neurogenesis [30, 58]. 
 
Brain-derived neurotrophic factor (BDNF) is an essential nervous system growth factor in the brain 
which maintains physiological processes of the normal, intact adult brain, including supporting 
neuronal activity, function and survival throughout life [58]. BDNF has a high affinity to the 
tropomyosin-related kinase receptor type B (TrkB), which is a widely expressed receptor 
throughout the adult brain [58]. This binding of BDNF to transmembrane TrkB leads to activation 
of phosphoinositide 3-kinases (PI3Ks), mitogen-activated protein kinases (MEKs), and 
extracellular signal-regulated kinases (ERKs) to deliver signals from the surface of cells to the 
nucleus, and promote neurite outgrowth and cellular differentiation [58]. Several lines of evidence 
indicate that BDNF significantly prevented cell death and promoted neuronal function in animal 
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models of CNS diseases [58].  In the study reported by Wurzelmann and coworkers, BDNF was 
shown to improved neurological and cognitive functions in mice with traumatic brain injury [59, 
60]. Moreover, BDNF protein significantly decreased apoptotic percentage of serum deprivation 
cell model and reduced the infarct area in middle cerebral artery occlusion (MCAO) model [61]. 
Therefore, the substantial neuroprotective effects of BDNF indicate a competitive therapeutic 
potential in the treatment of stroke. However, two main challenges limit the application of BDNF. 
First, limited amounts of BDNF reach the CNS, even in the stroke model where the blood-brain 
barrier (BBB) might have been disrupted [58]. Short half-life is another main hurdle in both clinical 
and in vivo studies [62, 63]. Due to the challenges of application of BDNF protein, this project 
proposes to deliver BDNF-DNA instead of protein into immortalized human cerebral 
microvascular endothelial cells (hCMEC/D3 cells). We propose that BDNF delivery to the 
endothelial cells is an important component in protecting the NVU against ischemic damage. 
 
Central hypothesis: We hypothesize that the hCMEC/D3 cell line, transfected with BDNF 
DNA/PEG-DET nanoparticles (NPs) with Pluronic P84 (Chapter 2) or BDNF DNA-containing 
extracellular vesicles (Chapter 3), will facilitate the expression of BDNF protein. 
 
The DNA molecule is the basic unit that stores the fundamental information of human life, which 
possesses a great potential for therapeutic application. In the past decades, delineating the human 
genome provided the basis for the development of DNA-based therapy, such as gene replacement 
and ablation [64]. Currently, gene therapy has evolved from an experimental technology into a 
viable strategy for a wide range of medical disorders [65]. Gene therapy is often used to correct a 
mutant gene by the introduction and expression of its correct copy, with the desired protein being 
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produced to mitigate the condition [65]. For example, mutations of the p53 gene are reported in 
50-60% of human cancers [66]. After reintroduction of wild-type p53, the cell proliferation was 
suppressed, and the survival of the treated mice was increased by more than 50% compared with 
control animals [66]. The high specificity of action is the most significant advantage of DNA-
based medications over currently available small molecules [65]. Advances in genetic engineering 
can allow precise targeting and minimize nonspecific toxicity. Huang and coworkers reported that 
the delivery of DNA encoding a diphtheria toxin suicide protein (DT-A) significantly reduced the 
ovarian tumor size, compared to the combination drug therapy  using cisplatin + paclitaxel [67]. 
In addition, the DT-A-treated mice did not result in significant weight loss and nonspecific toxicity 
to other organs, such as liver, spleen [67]. Therefore, the development of DNA-based 
pharmaceuticals offers great potential options for the treatment for a wide range of diseases, 
including cancer and neurological disorders. 
 
1.5.   Vectors/carriers for DNA delivery to the BBB. 
 
1.5.1. Polyplexes 
 
Since naked DNA is rapidly cleaved by nucleases, appropriate delivery methods are required to 
transfer genetic material into cells and tissues [68]. DNA delivery can be achieved using three 
types of techniques: vector-assisted delivery, electrical techniques and mechanical transfection 
[65]. Mechanical or electrical techniques deliver naked DNA into cells by the use of either 
microinjection or electroporation, which were discussed elsewhere [69, 70].  
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The technology of vector-assisted DNA delivery systems has matured from laboratory research 
into application stage for clinical trials of DNA – based therapeutics in the last few decades [71, 
72]. The development of safe and efficient vectors plays a critical role in the realization of the 
therapeutic potential of DNA-based drugs. Two types of DNA delivery systems are currently 
available, discriminated based on the carriers: viral and non-viral vectors [65]. The  viral vector 
has high transfection efficiency in vitro and in vivo: e.g., the retroviral vectors result in 45% – 95% 
of transfected cells [73]. However, the toxicity of the viral vectors shall not be ignored. Originating 
from viruses, the viral vectors may cause chronic infection (avian C-type retroviruses) and 
immunogenicity (recombinant adenoviral of adenovirus / rous sarcoma virus) [74, 75]. In addition, 
many other factors , such as the low capacity of those vectors for large size DNA (8 kilobase of 
exogenous DNA), limit their pharmaceutical applications [74].  
 
Although viral delivery systems have higher transfection efficiency for DNA delivery than non-
viral delivery systems, non-viral delivery systems overcome some of the limitations of viral 
vectors owing to their low immune response and easy assembly [76, 77]. This section will focus 
on vector-assisted delivery systems, especially non-viral vectors which utilize polymers to 
condense DNA into nanoparticles for delivery. In order to improve transfection efficiency and to 
circumvent systemic and subcellular obstacles, a huge library of vectors have been synthesized. 
Two major types of non-viral vectors are generally utilized in the formulation of DNA-based 
delivery systems: lipids and polymers.  Lipoplexes are nanoparticles that consist of an aqueous 
core locked in a phospholipid bilayer. DNA is either entrapped in the aqueous core or condensing 
them to the lipid layers [65]. Although lipoplexes provide high transfection efficiency compared 
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to many non-viral DNA delivery systems, cytotoxicity is a concern in numerous in vitro studies, 
and is mainly related to the use of cationic lipids [78-80]. 
 
Polymeric delivery systems, known as polyplexes, have drawn a great deal of attention as an 
alternative to viral delivery systems to deliver DNA into cells [81]. The basic mechanism of 
polyplex assembly is based on electrostatic interaction between the positive charge of cationic 
polymers and the negative charge of phosphate groups in DNA [82]. The net positive charge of 
cationic polyplexes also allow it to interact with negatively charged cell surface to enhance DNA 
uptake [83]. . Furthermore, a concept of block and graft copolymers of cationic and hydrophilic 
nonionic monomers was introduced as a potential approach to advance the non-viral gene delivery 
vectors [68]. For example, attachment of hydrophilic polymers (N-(2-Hydroxypropyl) 
methacrylamide, PHPMA) served as a surface shield around the positive charge of cationic 
polymer/DNA complexes to protect against unspecific interactions and promote extended 
circulation in system administration [84]. By applying the conjugation of functional elements to 
cationic polymers, these modifications increase the chance of the carriers to overcome the restraint 
of BBB and improve the transfection efficiency in BBB cell models.  For instance, pegylated 
polyethyleneimine (PEG-PEI) or pegylated poly(2-(dimethylamino) ethyl methacrylate) (PEG-
PDMAEMA) grafted with several peptides such as arginine, trans-golgi network (TGN) ligands, 
which had high affinity to the cell membranes, were reported to facilitate BBB targeting and 
increase gene expression in vitro and vivo transfection of brain [85-87].  
 
Poly (ethylene glycol)5k-poly (L-aspartate-diethylenetriamine)48 (PEG-DET) (Figure 1-2) is one 
of the promising A-B-type copolymers, which has received a lot of interest because of its low 
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cytotoxicity, high colloidal stability and high transfection efficiency, offering the possibility of 
their application in systemic gene delivery [83, 88-90]. The copolymer is comprised of a 
hydrophilic block PEG, and a polycation block, DET. The cationic polymers spontaneously 
interact with plasmid DNA (pDNA) to form biocompatible polyplexes with hydrophilic PEG 
surrounding the polyplex core.  
 
Figure 1-2 The structure of PEG-DET. 
 
In order to further enhance gene transfer of PEG-DET/DNA complexes, Pluronic, a nonionic block 
copolymer was involved. The structure of Pluronic is the poly (ethylene oxide) and poly(propylene 
oxide) arranged in a triblock structure: EOx-POy-EOx , which is widely used as an excipient in 
pharmaceutical applications [91, 92]. Pluronic P84 (Figure 1-3) was served as an excipient to 
enhance cellular uptake and nuclear import of pDNA, which was incorporated with a list of 
polycations including linear PEI, Exgen 500, biotin-modified PEG-PEI and  so on [93]. Several 
studies have reported that low concentrations of Pluronic (0.03% -1% w/v) significantly enhanced 
in vitro transfection activity of polyplexes through the activation of NF-κB signaling pathway [91, 
93, 94]. Zhao and coworkers used PEG-DET as polycation to condense pDNA to form polyplexes, 
referred to as DNA nanoparticles (NPs) in this work [95]. They demonstrated that 0.01-0.03% w/v 
Pluronic P84 significantly increased the transfection activity of DNA NPs by 18-30 fold in a 
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human cerebral microvascular endothelial cell line (hCMEC/D3), use here as an in vitro model of 
the BBB [95].  
 
 
Figure 1-3 The structure of Pluronic P84 (P84). 
 
Despite all the advantages of polymer carriers, they suffer from the relatively low transfection 
efficiency comparing to virus carriers because they did not originate from organism but chemically 
engineered into nanoparticles. Biological carriers i.e. extracellular vesicles are extracted from BBB 
cells and has a potential to improve the gene delivery.  
 
1.5.2. Biological carriers: Extracellular vesicles 
 
Extracellular vesicles (EVs) are generated by cells and secreted to the extracellular environment. 
Almost all cell types produce EVs. Based on their size, EVs are divided into three categories: 1) 
exosomes (EXOs) with diameters of 30-150 nm, 2) microvesicles (MVs) with diameters of 100-
1000 nm and  3) apoptotic bodies with diameters of 500-5000 nm [96].  
 
Exosomes are homogeneous particles in size. One of the proposed biogenesis of EXOs implicated 
that EXOs generated from the inward budding of endosomal membranes. With the help of four 
protein complexes, the endosomal sorting complex required for transport (ESCRT) – 0, I, II and 
III ubiquitinylated proteins are sequentially accumulated and formed  intraluminal vesicles (ILVs) 
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within large multivesicular bodies (MVBs), and were finally secreted to the intercellular 
environment [97, 98]. Distinct from EXOs, MVs are a heterogeneous population of membrane 
vesicles [99], which are directly shed from plasma membrane [100]. Similar to EXOs, the 
generation mechanisms of  MVs are still largely undefined, but recent research showed that 
ESCRT-I subunit tumor susceptibility gene 101 (Tsg101) and arrestin domain-containing protein 
1 (ARRDC1) might involve in the biogenesis of MVs [101, 102]. The commonly accepted 
biological function of EXOs and MVs is their role in intercellular communication between cells 
locally or at a distance [101]. For example, cancer cells secrete exosomes to modulate their 
microenvironment to resist apoptosis, facilitate cancel cell proliferation, angiogenesis, and 
migration in metastases via their miRNA content [103]. Meanwhile, EVs derived from stem cells 
such as MSCs or embryonic stem cells (ESCs) activate repair or differentiation processes by 
transferring functional miRNAs to promote repair of injured tissue and induce early stage of 
dedifferentiation [104]. Several studies showed that MSC-EXOs via intravenous administration 
were able to enter the brain to improve post-stroke neurodegeneration and induce long‐term 
neuroprotection associated with enhanced angiogenesis in animal studies [105] [106, 107]. 
 
The potential application of EXOs as vectors for targeted drug delivery has received much 
attention in recent years. It had a few advantages including, 1) the presence of protein and nucleic 
acids such as miRNAs and siRNAs in EXOs imply that such biological materials could be loaded 
into EXOs [108]; 2) EXOs might be well tolerated leading to long circulating half-life in 
circulation system, because they are endogenous and are widely distributed in biological fluids 
such as blood, urine and breast milk [108, 109]; 3) EXOs have an intrinsic ability to home to targets 
depending on their parent cells (for example, melanoma EXOs preferentially target to sentinel 
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lymph nodes [110]); 4) EXOs derived from tissue-specific cells can cross the physiological barriers 
and target the tissue via their natural surface proteins (for instance, EXOs extracted from brain 
endothelial cells such as brain endothelial bEND.3 would more likely display brain-specific 
biomarkers for delivery of molecules across the BBB [111]).  
 
Although they share similar role in intercellular communication as EXOs [108], MVs have some 
unique functions. Mitochondria is a key organelle found in most eukaryotic organisms, which 
generates most of the cell's supply of adenosine triphosphate (ATP), used as a source of chemical 
energy [112]. Mitochondria have been shown to be horizontally transferred between mammalian 
cells via vesicular transfer [113]. Several studies indicated that this transfer allowed the exogenous 
replacement of damaged mitochondria, restored ATP levels and improved lung function [113]. For 
example, astrocytes produced functional extracellular mitochondria to support rat cortical neuronal 
viability when subjected to oxygen-glucose deprivation [114]. Thus, horizontal transfer of 
mitochondria is a viable strategy to revive bioenergetics injured tissues. Mitochondria and 
mitochondrial DNA (mtDNA) were relatively enriched in MV samples (89 mitochondrial proteins 
in MVs, one mitochondrial protein in EXOs) as determined using shotgun proteomics, suggesting 
that mitochondria may be packaged in MVs [115]. This hypothesis was supported by Phinney et 
al., who reported that mesenchymal stem cells (MSCs)-derived MVs contained mitochondria and 
increased survival rate of recipient cells by reducing reactive oxygen species [116]. Moreover, 
after treatment of MSC derived MVs, the oxygen consumption rate of macrophages increased, 
compared to untreated macrophages, which indicated that MV-mediated mitochondrial 
transportation improved macrophage function by improving mitochondrial bioenergetics [116].   
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Therefore, the vectors like exosomes and MVs, which have intrinsic bio-functions, may 
outperform non-biological vectors in nano drug delivery for the treatment of stroke.   
 
Natural vesicles such as EXOs and MVs have the potential to overcome some of the limitations of 
synthetic vectors including non-specificity and the toxicity to cell membranes. Alvarez-Erviti  and 
coworkers [117] developed siRNA-loaded exosomes targeting β-site amyloid precursor protein 
cleaving enzyme 1 (BACE1) mRNA for the treatment of Alzheimer’s disease. In this study, the 
surface of the exosomes was engineered with neuron-specific rabies viral glycoprotein (RVG) 
peptide, which allow the vesicles to accumulate in the brain and reduce the expression levels of 
BACE1 mRNA (60%) and protein (62%). Kanada et al. reported the reporter-encoding nucleic 
acids including mRNA, and siRNA are more efficiently loaded into MVs than EXOs, and only 
MVs could functionally transfer pDNA (luciferase pDNA) to recipient cells in both in vitro and in 
vivo [118].  They suggested that pDNA delivery via MVs was transported from endosomes to the 
nucleus of recipient cells and then transcribed into mRNA for protein expression, whereas DNAs 
delivered by EXOs were likely degraded during transport pathway. Moreover, Kanada et al found 
that Luc–RFP-encoding pDNA (8567 bp) delivered by MVs resulted in lower gene expression 
than Luc-encoding pDNA (7090 bp), which indicated that the size of the delivered pDNA was 
important for efficient delivery of pDNA via MVs [118].  
 
1.6. The future of EVs 
 
Despite the exciting findings of the drug delivery potential of EXOs and MVs, there are still 
limitations in its clinical applications. There is little understanding of the mechanism of EXO and 
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MV penetration through biological barriers. Record and coworkers proposed that EXOs might 
cross several barriers by internalizing into the MVBs of recipient cells, then releasing again and 
re-internalizing into the MVBs of secondary recipient cells, and so on [119]. However, no 
definitive evidence was provided to support their claim. Understanding the mechanism of 
trafficking across barriers can show new gateways into tissues that have not been exploited for 
conventional drug delivery systems, and the mechanism could be used for the optimization of 
transfection efficiency of EVs. Given the published evidence on the role of EVs derived from 
breast cancer cells in facilitating the convention of normal mammary epithelial cells in 
tumorigenesis [120], thus it would be important to carefully characterize the composition of EVs 
to minimize unwanted side effects.  The most commonly used method for isolating exosomes is 
ultracentrifugation at 100,000–120,000 × g [100, 121]. However, the biggest problem of current 
method is not sufficiently separating EV subtypes and producing a completely pure sample of EVs 
[100]. Further filtration of EVs under pressure after ultracentrifugation not only continues to 
decrease the yield, but also leads to a concurrent protein loss [100]. Several reagents were 
developed to purify EVs such as OptiPrep™ (iodixanol) density gradient medium used by Codiak 
BioSciences, but the technique requires large amount of sample, and the process is laborious [122, 
123]. Meanwhile, immunocapture techniques based on specific markers on the surface of 
exosomes can enrich the concentration of EVs but the cost of this purification process is expensive 
and confound the interpretation of the results due to non-specific protein binding [122]. Hence, the 
lack of a gold standard method to isolate EV could hinder its clinical application. s. Loading of 
gene material into MVs is relatively inefficient and cost-ineffective (less than 20% gene loading) 
[117, 118, 124]. Thus, novel gene loading methods are needed to increase loading efficiency and 
decrease the cost. Several studies reported that 3′-uridylated miRNAs was highly accumulated in 
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exosomes than in cells [124, 125]. Engineering the structure of nucleic acid by attachment of 3′-
end uridylic acid might help to concentrate gene in EXOs.   
 
Taken together, EVs appear to possess some remarkable properties for the delivery of gene 
materials. Careful analysis of the compositions of EVs and gateways to tissues and cells can lead 
us to understand the critical molecules involved in its trafficking and vesicle characteristics for 
future applications. Although further study on EVs is a promising direction for developing next 
generation drug delivery systems, it is worthwhile to note that the clinical potential of EVs highly 
rely on the development of their purification and optimization of gene loading technology.  
 
1.7. Summary  
 
Stroke is a major cause of death in the United State and results in breakdown of the connection 
between BBB and neuronal function of NVU. However, due to the role of the BBB, a significant 
number of drugs suffer a low CNS permeability. Although the tPA is an available therapy for 
treatment of acute stroke, the drawbacks of tPA cannot be ignored. A novel therapy is in high 
demand, especially the regenerative therapies which enhance recovery for neurological deficits. 
Owing to the neurological function of BDNF, delivery of BDNF DNA is a competitive candidate 
for stroke treatment. Since naked DNA is not suitable for in vitro/in vivo studies, the techniques 
of vectors were discussed in this review. One is PEG-DET with P84, which has low cytotoxicity 
and high transfection efficiency, offering the possibility of the application in systemic gene 
delivery. Meanwhile, the biological carrier EVs was discussed, because of intrinsic bio-functions, 
  
20 
which could outperform non-biological vectors to deliver BDNF DNA into cells for the treatment 
of stroke. 
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Chapter 2: Gene Delivery via PEG-DET and P84 in a Human BBB 
Model 
 
2.1.  Introduction 
 
Brain endothelial cells and neuronal cells produce several growth factors and signals to stimulate 
the proliferation and differentiation of each other to respond the changes in local environment [30]. 
Brain-derived neurotrophic factor (BDNF) protein, a type of neurotrophin derived from brain 
endothelial cells, binds to the NF-κB receptor on the surface of neuronal cells and increases 
neuronal survival [126]. For example, BDNF protein significantly reduced the infarct area in 
middle cerebral artery occlusion (MCAO) model [61]. Moreover, intravenous infusion of BDNF 
showed the behavioral improvement such as total distance travel and movement time in stroke rats 
[127]. However, the short half-life of BDNF protein and the lack of effective delivery methods 
across the blood-brain barrier (BBB) limit its medical applications [58, 128]. To overcome the 
disadvantages of delivering BDNF protein, we proposed a therapy to deliver BDNF DNA instead 
of BDNF protein to brain endothelial cells, which can then be transcribed and translated to produce 
BDNF protein.  
 
Poly (ethylene glycol)5k-poly (L-aspartate-diethylenetriamine)48 (PEG-DET) attracted a great deal 
of interest for DNA delivery because of its low cytotoxicity and high transfection efficiency [83, 
88, 89]. We used it as a polycation to condense plasmid DNA (pDNA) to form DNA nanoparticles 
(NPs). The degree of DNA/PEG-DET condensation and particle size are the among the 
characteristics that can affect then transfection activity of the nanoparticles.  
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Pluronic is a nonionic block copolymer, comprised of hydrophil ic ethylene oxide (EO) and 
hydrophobic propylene oxide (PO) blocks arranged in a triblock structure: EOx-POy-EOx , is 
widely used as an excipient in pharmaceutical applications [91, 92]. Several studies reported that 
low concentrations of Pluronic (0.03% -1% w/v) significantly enhanced in vitro transfection 
activity of DNA NPs through the activation of NF-κB signaling pathway [91, 93, 94].  
 
Cell models of the BBB are helpful tools to study the transfection of DNA NPs. Human cerebral 
microvascular endothelial cell line (hCMEC/D3) is one of the most commonly used cell lines for 
in vitro BBB models [42, 129-133]. Despite its comparatively low transendothelial electrical 
resistance (TEER, a measure of barrier tightness), this cell line retains most of the morphological 
and functional properties of brain endothelial cells, even as a monoculture in the absence of 
cocultured glial cells [131, 132]. The hCMEC/D3 cell line expresses multiple BBB markers 
including active transporters and receptors until approximately passage 35 without undergoing 
dedifferentiation to unstable phenotypes [131-135]. The most striking characteristic of 
hCMEC/D3 cell line as an in vitro BBB model is its ability to form TJs [130, 133, 135, 136]. It 
should be noted that although in many studies stem cell-derived BBB models showed higher 
permeability than hCMEC/D3 cell line and they do express some BBB markers, they are yet to 
evolve as a commonly used BBB cell model [137]. Importantly, stem-cell derived BBB models 
remain to be characterized with respect to maximum passage numbers that allow the cells to 
maintain stable BBB phenotypes [138].  
 
  
23 
Specific hypothesis: We hypothesize that the hCMEC/D3 cell line, transfected with BDNF 
DNA/PEG-DET nanoparticles (NPs) with Pluronic P84, will facilitate the expression of BDNF 
protein. 
 
Several studies reported that Pluronic increased the permeability of Caco-2 monolayers, which 
resulted in cytotoxicity [18, 36]. We developed a method to measure paracellular permeability 
using lucifer yellow (LY Papp) assay to optimize the culturing time for the formation of intact 
barrier and we demonstrated that PEG-DET DNA NPs with P84 did not significantly affect the 
barrier tightness of hCMEC/ D3 monolayers [139]. 
 
Lucifer yellow is a hydrophilic dye with distinct excitation/emission peaks and avoids the need to 
radiolabel tracer molecules such as sucrose, mannitol or inulin. The fluorescence values of LY can 
be used to directly calculate its paracellular permeability across the BBB monolayers. Also, 
compared to many commercially available dyes used in biomedical fields that suffer from small 
Stokes shifts such as fluorescein [140], the Stokes shift of LY is about 108 nm with sufficient 
spectral separation, thus allowing LY  fluorescence data to determine paracellular permeability. 
We used western blot as an orthogonal technique to demonstrate changes in expression of the tight 
junction marker protein, ZO-1, over culturing time. The expression of ZO-1 detected via western 
blot was used to complement the LY Papp data. 
 
After we confirmed that the DNA NPs with 0.03% P84 did not affect the barrier integrity, we 
investigated the delivery of BDNF pDNA and expression of BDNF in the hCMEC/D3 cell line.  
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2.2.  Materials and Methods 
 
2.2.1.  Materials 
 
The following materials were procured from the respective suppliers indicated in parentheses. 
hCMEC/D3 cell line (Cat# 102114.3C-P25, Cedarlane Laboratories); Plasmid DNA encoding 
luciferase gene, gWiz-Luc (Cat# 5000-500, Aldevron); Lucifer yellow CH dilithium salt (Cat# 
155267, Invitrogen™); Transwell inserts with polyethylene terephthalate (PET) track -etched 
membranes (Cat #353095, pore size, micron: 0.4, pore density 2.0±0.2 × 106
𝑝𝑜𝑟𝑒𝑠
𝑐𝑚2
, effective 
growth area of membrane: 0.3 cm2, Falcon®); Tissue culture flask (Cat# 25-207, growth area: 
75cm2, Olympus Plastics); 24-well Flat Bottom (Cat# 25-107, growth area: 1.93 cm2, Olympus 
Plastics), Black 96-Well Immuno Plates (Cat# 437111, Thermo Scientific™); Spinner-minimum 
essential medium (S-MEM 1X, Cat# 1951695, gibco®); Endothelial cell basal medium-2 (EBM-
2, Cat# CC-3156, Clonetics); ZO-1 Polyclonal Antibody (Cat# 61-7300, ThermoFisher); 
phosphate buffered saline (PBS 1x, Cat# SH3025601, HyClone); Collagen Type I (Cat# 354236, 
Discovery Labware, Inc); Pierce™ BCA Protein Assay Kit (Cat# 23227, Thermo Scientific™); 
Cell Culture Lysis 5X Reagent (Cat# E1531, Promega); Beetle Luciferin, Potassium Salt (Cat# 
E1601, Promega); Cell TiterGlo Luminscent Cell viability assay (Cat# G7572, Promega); BDNF 
Emax® Immuno Assay System (Cat# C076, Promega), Amicon UltraCentrifugal Filter Unit 
(SKU: UFC200324, Millipore Sigma). General laboratory chemicals and solvents were obtained 
from Fisher Scientific and used without further purification. 
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2.2.2.  Methods 
 
2.2.2.1.  Prepare DNA Nanoparticles (DNA NPs) 
 
The DNA NPs were prepared using electrostatic interaction between PEG-DET and calf thymus 
DNA (ctDNA) (Figure 2-1)  for all physicochemical characterization studies. Specifically, the 
ctDNA was transferred from -20°C storage condition to room temperature (RT) and thawed 
completely on ice to minimize temperature stress. The stock solution of ctDNA (710 µg/mL) was 
diluted in 10 mM sodium acetate (NaAc) buffer (pH 5.0) to the working concentration of 20–40 
µg/mL [68]. The diluted DNA solution was gently vortexed for 30 seconds on an analog vortex 
mixer (Fisherbrand, USA), knob position setting at 4, and then standing for 10 min at RT. 
Afterward, the PEG-DET was added along the walls of the tube while holding the tube in a nearly 
horizontal position. The mixture of PEG-DET and DNA was gently vortexed for 10s and incubated 
for additional 30 min at RT for the complete formation of DNA NPs [141]. The ratio of positively 
chargeable polymer amine (N=nitrogen) groups to negatively charged nucleic acid phosphate (P) 
groups (N/P ratio) was calculated by following equation (Eq.) 2-1:  
 
𝑁 𝑃⁄  𝑟𝑎𝑡𝑖𝑜 =  
𝑀𝑎𝑠𝑠 𝑜𝑓 𝑐𝑎𝑡𝑖𝑜𝑛𝑖𝑐 𝑝𝑜𝑙𝑦𝑚𝑒𝑟
(𝑀𝑎𝑠𝑠 𝐶ℎ𝑎𝑟𝑔𝑒)⁄ 𝑐𝑎𝑡𝑖𝑜𝑛𝑖𝑐 𝑝𝑜𝑙𝑦𝑚𝑒𝑟
𝑀𝑎𝑠𝑠 𝑜𝑓 𝐷𝑁𝐴
(𝑀𝑎𝑠𝑠 𝐶ℎ𝑎𝑟𝑔𝑒⁄ )𝐷𝑁𝐴
                                                                                Eq.2-1  
 
Equation 2-1 N/P ratio calculation: the ratio of moles of the amine groups of cationic polymers to 
those of the phosphate groups of DNAs. Mass of cationic polymers means total weighed amount 
of cationic polymer; (Mass Charge)⁄ cationic polymers refers to the molecular weight of cationic 
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polymer (poly (ethyleneglycol)5k-block-polyaspartamide with 48 diethylenetriamine side chains 
(PEG-DET)) normalized to the number of charged primary amines (48) per cationic polymer 
(mol/mol), this value for our polymer is 306 Da; Mass of DNA means total amount of DNA used 
in the formulation obtained by multiplying the volume and concentration in 
mg/mL;  (Mass Charge⁄ )DNArefers to the molecular weight of DNA normalized to number of 
phosphate group per double-stranded DNA (325 Da per nucleobase). 
 
Figure 2-1 The formation of DNA NPs through the electrostatic interaction between the 
diethylenetriamine side chains of cationic polymer and plasmid DNA (pDNA).  
 
2.2.2.2. Determine DNA Condensation of PEG-DET Using Ethidium Bromide (EtBr) 
Exclusion Assay 
 
The EtBr was used as the intercalator to investigate the formation of DNA NPs condensed from 
PEG-DET and DNA. The EtBr can bind to helical regions of the interior DNA molecule so that it 
stacks between DNA base pairs. The fluorescent yield of intercalated EtBr dye is many folds higher 
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than the free EtBr dye. The maximum absorption of EtBr is in the ultraviolet (UV) range, and the 
excitation of EtBr emits orange light with a wavelength of 605 nm [142]. The ctDNA sample was 
prepared by diluting stock solution of ctDNA to 20 µg/mL in 2.1 mL 10 mM NaAc. The blank 
solution was 2.1 mL 10 mM NaAc.  2.1 µg EtBr was added into ctDNA sample and blank solution. 
Afterwards, 2 mL ctDNA sample and blank solution were aspirated into cuvettes separately. A 
series of DNA NPs in the cuvettes were prepared by following the steps described in 2.2.2.1 to 
add precalculated PEG-DET based on required N/P ratio, including 0, 0.3, 0.5, 0.8, 1.0, 1.3, 2.0, 
2.7, 3.3, 4.0, 4.7, 5.3, 6.7, 8.0, 10.6. The fluorescence of EtBr in each sample of DNA NP were 
measured by Fluoromax-4 (Horiba, Japan) (set points: excitation: 545 nm, emission: 595 nm, split: 
3 nm).  
 
2.2.2.3.  Determine DNA Condensation of PEG-DET Using Gel Retardation Assay  
 
The gel retardation was applied as a second method to check the DNA condensation.  First, the 0.8 
g agarose was suspended in 100 mL of hot 1X Tris-Borate-EDTA (TBE) buffer. When the 
temperature of agarose solution reached at 60°C, 50 µg EtBr was added to the solution. The liquid 
was   carefully poured into gel cast to avoid bubbles. A desired comb was placed and let solidify 
for 1 h. After the solidification, the comb was carefully removed, and the gel cast was carefully 
positioned in line with the side chambers of the electrophoresis equipment. Along the wells, 20 μL 
of 2.5 μg standard DNA ladder and samples of 9.5 μg ctDNA with different N/P ratios, including 
0.0, 0.5, 1.0, 2.0, 5.0, 8.0, 10.0 were added. The electrophoresis system (FisherBiotech, FB-VE10-
1, USA) ran for 50 min at 120 V, 100 mA with Tris-acetate (TAE) running buffer. Then, the gel 
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was slowly taken out from cast and exposed to UV to take the pictures by a imager with UV 
fluorescence (ProteinSimple, USA).  
 
2.2.2.4.  Characterize Particle Size and Zeta Potential of DNA NPs 
 
The particle size and zeta potential of DNA NPs were measured by the Malvern Zetasizer Nano-S 
(Malvern Instruments, UK) using dynamic light scattering (DLS) [143]. A series of DNA NP 
preparations containing 15 μg ctDNA with different N/P ratios (0, 2, 10) were prepared 10 mM 
NaAc buffer (pH 5.0)  
 
2.2.2.5.  Lucifer Yellow Apparent permeability (LY Papp) Assay 
 
A LY Papp assay was developed to understand the effect of culturing time on the apparent kinetics 
of TJ barrier formation. Tissue culture inserts with microporous membranes (pore size: 0.4 µm, 
material: polyethylene terephthalate (PET)), shown in Figure 2-2, were placed into a 24-well 
culture plate. Collagen type I (0.15 mg/mL, 400 μL) was added in each tissue culture insert and 
incubated for 1 h in the CO2 incubator (37°C, 5% CO2). Then, the collagen solution was removed, 
and the culture inserts were gently washed with 0.4 mL 1X PBS buffer. The hCMEC/D3 cells 
were plated with the density of 50,000 cells/cm2 in the cell inserts (15,000 cells in 500 µL medium).  
 
For determining LY Papp on each day post-seeding (Figure 2-2), growth medium in the basolateral 
side was replaced with 1.5 mL of pre-warmed (37 °C) transport buffer (25 mM HEPES, 145 mM 
NaCl, 3 mM KCl, 1 mM CaCl2, 0.5 mM MgCl2, 1 mM NaH2PO4, 5 mM glucose, pH 7.4). For 
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determining the Papp in transfected hCMEC/D3 cells (Figure 2-3), the cells were transfected by 
assigned amount of DNA NPs with P84 (Table 2-1) for 4 h following the steps described in 2.2.2.8. 
The wells were then gently washed using sterile 1X PBS buffer. In the apical side, 58.3 µL of 20 
µM LY solution was added into each culture insert. At least 50 μL of the 20 µM LY solution was 
saved as initial mass for calculation of Papp coefficient. To minimize the decay of LY fluorescence 
intensity, light exposure should be limited. The 24-well plate was incubated in a mini shaker 
(Thermo Scientific, USA) at 37 °C, 100 rpm for 60 min. Then, 30 μL and 500 μL of the LY sample 
was transferred from each apical and basolateral compartment to pre-labeled tubes. The 20 µM 
LY solution and the samples from apical side were diluted 10-fold using transport buffer to avoid 
potential overload and damage of fluorescence detector. A series of LY standards were prepared 
for the standard curve (39.00 nM, 78.13 nM, 156.25 nM, 312 nM, 625 nM, 1250 nM, 2500 nM). 
After that, 100 μL of each standard (in duplicate), apical and basolateral sample were added into 
each well in a black 96-well plate (Figure 2-3). The LY fluorescence intensity of samples was 
measured by using a SpectraMax i3 (Molecular Devices, USA) plate reader (set points: excitation 
428 nm, emission 536 nm, split: 3 nm). The Papp coefficient and the % LY recovery was calculated 
by equation 2-2 and 2-3.  
 
𝑃𝑎𝑝𝑝 (
𝑐𝑚
𝑚𝑖𝑛
) = 𝑉𝐴/(𝐴𝑀𝐴0) × (∆𝑀𝐵/∆𝑡) or 𝑃𝑎𝑝𝑝 (
𝑐𝑚
𝑚𝑖𝑛
) =  𝑉𝐵/(𝐴𝐶𝐴0) × (∆𝐶𝐵/∆𝑡)               Eq 2-2 
Equation 2-2 Formulae for calculating Papp values. VA: volume in the apical compartment; VB: 
volume in the basolateral compartment; A: the surface area of the tissue culture insert membrane 
(0.3 cm2); MA0: the initial mass in the apical compartment; ΔMB/Δt: the change of mass over time 
in the basolateral compartment; CA0: the initial concentration in the apical compartment; ∆CB/∆t: 
the change in concentration over time in the basolateral compartment. 
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Recovery (%) = 
𝑀𝐴𝑓  +𝑀𝐵𝑓
𝑀𝐴0
 × 100%                                                                                         Eq 2-3 
Equation 2-3 Formulae for the recovery percentage of LY Papp assay. MAf is the mass in the apical 
compartment at the end time point, MBf is the mass in the basolateral compartment at the end time 
point, MA0 is the initial mass in the apical compartment [144]. The initial mass (MA0) is calculated 
based on the volume of the 20 µM LY solution in this experiment. 
 
 
Figure 2-2 The 24-well plate setup containing tissue culture inserts for LY Papp study to understand 
the effect of culturing time on apparent kinetics of TJ barrier formation.  
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Figure 2-3 The cytocompatibility of DNA NPs with 0.03% P84 on TJ intergrity was evaluated in 
tissue culture inserts. The DNA NPs with 0.03% P84 and calcium-free medium were incubated 
with hCMEC/D3 cells for 4 and 24 hours. After washing cells by 1X PBS buffer, the LY (20 µM) 
solution was added into tissue culture inserts and incubated at 37°C and 100 rpm for 1 h. Then, the 
fluorescence of LY from apical and basolateral sides were measured by plate reader.  
 
2.2.2.6.  Calcium depletion study to determine the effect of blocking TJ formation 
 
In this experiment, all types of media were pre-warmed at 37°C.  After the initial 7 days of cell 
culture, growth medium was removed from the culture inserts. The wells were gently washed by 
calcium-free medium to remove calcium ion from the culture inserts. Then, 500 µL S-MEM 1X 
medium was added into the inserts, and then incubated for 24 hours at 37°C and 5% CO 2 
environment. After the incubation, the S-MEM 1X medium was removed and the wells were 
washed using 1X PBS buffer. The LY Papp assay was conducted in the steps following 2.2.2.5.  
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2.2.2.7.  Western blot to determine the expression of the tight junction protein, ZO-1  
 
The hCMEC/D3 cells were seeded at a density of 50,000 cell/cm2 in a collagen-coated 12-well 
tissue culture plate. On each day 3, day 5, day 7, day 10 post-seeding and on day 7 (cells pre-
incubated with calcium free medium), the growth medium was removed and gently washed twice 
with 2 mL ice-cold 1x PBS. Then, 300 µL mixture of ice-cold 1X RIPA lysis buffer containing 3 
µg/mL aprotinin was added in each well. After two freeze-thaw cycles (-80°C), the cells were 
scraped using a cold plastic cell scraper. The cell lysates were collected in microfuge tubes. Then, 
the tubes were centrifuged at 200 x g for 30 min at 4°C. The supernatant was collected into clean 
tubes and placed on ice. The total amount of cellular protein in the supernatant was measured using 
the BCA assay kit by following the manufacturer’s protocol. 
 
The 40 μg total protein in the supernatant was aliquoted and denatured with 1X Laemmli buffer at 
95°C, 5 min and was subjected to electrophoresis in a reducing 6–7.5% sodium dodecyl sulfate 
polyacrylamide gel (SDS-PAGE) (90 V, 10 min through stacking gel, 120 V through resolving 
gels). The separated proteins were transferred onto a nitrocellulose membrane with pH 8.5 transfer 
buffer which contains 192 mM Glycine, 25 mM Tris Base, 10% methanol and 0.1% SDS (75 V, 
110 minutes at RT). After washing the membrane by using Tris-buffered saline containing 0.1% 
Tween 20 (T-TBS), the blocking solution (1:1 LiCOR-Odyssey Block: 1X Tris Buffered Saline) 
was applied to block the membranes for 60 min. The membrane was carefully cut into two strips. 
The strip with low molecular weight was incubated with GAPDH antibody (dilution, 1: 10,000). 
The strip with high molecular weight was incubated with ZO-1 monoclonal antibody (dilution, 1: 
900). Both strips were incubated with primary antibodies overnight (beyond 12 hours) at 4˚C. Then, 
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the ZO-1 and GAPDH membranes were incubated with donkey anti-mouse IgG (dilution, 
1:50,000). After washing the membranes using T-TBS, the membranes were imaged in the 700 
channel by using on an Odyssey CLx Imager (Li-COR, USA). 
 
2.2.2.8.  Transfection efficiency of DNA NPs with Pluronic P84 in hCMEC/D3 cells 
 
The hCMEC/D3 cells were seeded with the density of 50,000 cell/cm2 in a 48-well plate or culture 
inserts and grew for 7 days in the incubator (37°C, 5% CO2). For each treatment group, the 
assigned amount of DNA NPs with P84 was mixed with complete growth medium and added to 
each well based on Table 2-1. After 4 h incubation, the transfection mixture was removed and 
washed with pre-warmed sterile 1X PBS buffer. Then, the cells were incubated for additional 24 
h with 500 µL pre-warmed culture medium to allow luciferase production. Afterwards, growth 
medium was removed completely, and the wells were washed with cold 1X PBS. The transfected 
cells were lysed by 100 μL of ice-cold luciferase cell culture lysis 1X reagent per well. For the 
measurement of the luciferase protein content, 20 μL of cell lysate and 100 μL of luciferin and 
luciferase assay buffer (20 mM glycylglycine (pH 8), 1 mM MgCl2, 0.1 mM EDTA, 3.5 mM DTT, 
0.5 mM ATP, 0.27 mM coenzyme A) were added into a 1.5 mL tube. The beetle luciferin was 
synthesized by luciferase in the presence of Mg2+, ATP and molecular oxygen and emitted the 
luminescence. The luminescence of the sample was measured on an ultrasensitive single tube 
luminometer for 10 s (GloMax®, USA).  The relative light units (RLU) were normalized against 
protein concentration in the cell extracts, measured from a bicinchoninic acid (BCA) assay. The 
peptide bonds in protein reduced Cu2+ ions to Cu1+ in an alkaline medium. Then, two molecules 
of bicinchoninic acid chelated with each Cu1+ to form purple-colored reaction product and 
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exhibited a strong absorbance at 562 nm via SpectraMax i3 plate reader [145].  Luciferase activity 
was reported as relative light units (RLU/mg protein in the cell lysates). Every transfection 
experiment was repeated at least three times. 
 
Table 2-1 Table of transfection formulation. The rule-of-thumb for DNA NP dosing is 0.5 μg DNA 
for ca. 1 cm2 growth area.  
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Experimental 
setup 
Sample 
name 
Volume 
of 
1mg/mL 
plasmid 
DNA 
(µL) 
Volume of 
10 mM 
NaAc 
buffer, pH 
5(µL) 
Volume 
of 5 
mg/mL 
polymer 
Volume of 
10% w/w. 
P84 (µL)   
Volume of 
growth 
medium (µL) 
(µL)   
Tissue 
culture insert 
Control, 
untreated 
cells 
0 0 
0 
0 
58.30 
Naked DNA 
0.16 
8.14 
50.00 
DNA NP 7.84 
0.30 
DNA NP + 
0.01% P84 
7.67 0.17 
DNA NP + 
0.03% P84 
7.26 0.058 
48-well plate 
Control, 
untreated 
cells 
0 0 
0 
0 
175.00 
Naked DNA 
0.50 
24.50 
150.00 
DNA NP 23.56 
0.94 DNA NP + 
0.01% P84 
23.39 0.18 
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DNA NP + 
0.03% P84 
23.04 0.52 
96-well plate 
Control, 
untreated 
cells 
0 
0 0 
0 
68.10 
Naked DNA 
0.20 58.40 
DNA NP 9.35 
0.37 
DNA NP + 
0.01% P84 
8.93 0.07 
DNA NP + 
0.03% P84 
9.07 0.20 
 
 
2.2.2.9.  Cytocompatibility of DNA NPs with Pluronic P84  
 
The hCMEC/D3 cells were seeded with the density of 50,000 cell/cm2 in a 96 well plate and grew 
for 7 days in the incubator (37°C, 5% CO2). The cells were transfected with 9.7 μL of DNA NPs 
(Table 2-1) with P84 containing 0.2 μg luc pDNA and 58.4 μL of complete growth medium for 4 
h. Then, the transfection mixture was removed, and the wells were gently washed with pre-warmed 
PBS 1X buffer twice to remove the treatment reagents completely. The amount of ATP is directly 
proportional to the number of cells present in culture [146]. Thus, 75 µL fresh pre-warmed medium 
and ATP assay reagent in a 1:1 dilution was added into the plate. The ATP assay reagent contained 
cell lysis buffer, thermostable luciferase and beetle luciferin. The mono-oxygenation of luciferin 
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was catalyzed by luciferase in the presence of Mg2+, ATP and molecular oxygen. The plate was 
placed on a nutating shaker for 15 min at room temperature, and then 60 µL of solution from each 
well was transferred into a white 96-well plate. The white plate was read by the plate reader with 
a 1 sec integration time. The amount of ATP present is proportional to the generation of a 
luminescent signal. The percent (%) cell viability was calculated using following Equation 2-4. 
 
Relative cell viability (%) = 
𝐿𝑢𝑚𝑖𝑛𝑒𝑠𝑐𝑒𝑛𝑐𝑒 𝑜𝑓 𝑡𝑟𝑎𝑛𝑠𝑓𝑒𝑐𝑡𝑒𝑑 𝑐𝑒𝑙𝑙𝑠
𝐿𝑢𝑚𝑖𝑛𝑒𝑠𝑐𝑒𝑛𝑐𝑒 𝑜𝑓 𝑐𝑜𝑛𝑡𝑟𝑜𝑙,   𝑢𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑐𝑒𝑙𝑙𝑠 
× 100                            Eq.2-4 
Equation 2-4 Formulae for the percentage of the cell viability. The luminescence of transfected 
cells represents that the light was emitted from lysate of transfected cells; The luminescence of 
control, untreated cells represents that the light was emitted from lysate of untreated cells.  
 
2.2.2.10.  Transfection of BDNF pDNA NPs 
 
The hCMEC/D3 cells were seeded with the density of 50,000 cell/cm2 in a 24-well plate and grew 
for 7 days in the incubator (37°C, 5% CO2). The cells were transfected by DNA NP N/P 10 with 
different reagents (Table 2-2). After 4 h incubation, the transfection reagents were replaced with 
fresh growth medium for production of BDNF protein for 48 h. The growth medium after 48 h 
incubation was collected from 24 well plate into 1.5 mL tubes and concentrated from 1 mL to 200 
µL using ultracentrifugal filter unit (Millipore Sigma, USA). The production of BDNF protein was 
measured using the BDNF Emax® Immuno Assay System. In this system, a 96 well plate was 
coated with Anti-BDNF monoclonal antibody (mAb) to bind soluble BDNF. The captured BDNF 
bound the second, specific, BDNF polyclonal antibody (pAb).  After washing the 96 well plate, 
the amount of specifically bound pAb was detected using a species-specific anti-IgY antibody 
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conjugated to horseradish peroxidase (HRP) as a tertiary reactant. The bound conjugates incubated 
with a chromogenic substrate, and the color change at A450 was measured using a SpectraMax i3 
plate reader.  
 
Table 2-2 Two level two factor design for the formulation of BDNF pDNA NPs.  
Factors Level 1 Level 2 
DNA contain 0.5 µg BDNF pDNA 2 µg BDNF pDNA 
P84 0.03% 0.06% 
 
2.2.2.11. Statistics analysis 
 
All data was analyzed using Microsoft Excel. All statistics were presented as the format of mean 
and standard error (SE). Statistical comparisons were performed using unpaired t-test. One-way 
ANOVA was applied for contrast of multiple groups. Statistically significant differences were 
marked with asterisks (*p < 0.05, **p < 0.01, ***p < 0.001).  
 
2.3.  Results 
 
2.3.1.  PEG-DET condensed DNA into DNA NPs 
 
The result of the gel retardation assay indicated PEG-DET condensed DNA when the N/P ratio of 
PEG-DET/DNA was greater than 2 (Figure 2-4a). In contrast, there was a free DNA band appeared 
when N/P<2, suggesting incomplete complexation (Figure 2-4a).  
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The formation of DNA NPs was also confirmed using the EtBr dye-exclusion assay. In the Figure 
2-4b, the fluorescence intensity of EtBr deceased with an increase in the N/P ratio. At N/P = 2, the 
relative fluorescence intensity unit (RFU) reached a plateau. It indicated that PEG-DET condensed 
DNA at the maximum efficiency when N/P was greater than 2, consistent with the result of gel 
retardation.  
 
 
Figure 2-4  DNA Condensation was determined by gel retardation assay and EtBr exclusion assay. 
a) Gel retardation assay of PEG-DET/ctDNA at different N/P ratios. The concentration of ctDNA 
is 20 µg/mL in each lane. b) The relative fluorescence unit (RFU) of EtBr in solution with pDNA 
and PEG-DET at various N/P ratios. 
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2.3.2.  Particle Size and Zeta Potential of DNA NPs 
 
The particle size and zeta potential of N/P 0, N/P 2, and N/P 10 was showed in Figure 2-5a and b. 
It revealed that the increase in the N/P ratio resulted in the increase in the particle size and zeta 
potential from N/P 0 to N/P 10. When the N/P ratio was 0, the particle size was 544.0 ± 98.6 nm 
with polydispersity index (PdI) 0.76 ± 0.03, which was the largest among all three levels. The 
particle size deceased with the addition of PEG-DET. Generally, DNA NPs enter mammalian cells 
via a endocytosis process in which the is limited to preferred particle size smaller than 150 nm 
[147, 148]. The particle size of N/P 2 was about 111.4 ± 2.1 nm, which was below the preferred 
particle size, but the PdI of N/P 2 (0.41 ± 0.02) was broad [149]. Thus, the sample of N/P 10 was 
considered as the optimal ratio for further transfection studies. As listed in Figure 2-5a, the results 
showed that the zeta potential changed from negative charge to positive charge with the addition 
of PEG-DET (from -50.0 ± 2.9 mV to 8.3 ± 0.3 mV).  
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Figure 2-5 a) The results of particle size and zeta potential measurements for PEG-DET DNA NPs 
using DLS. b) Particle size distribution of PEG-DET DNA NPs using DLS. The concentration of 
ctDNA is 20 µg/mL in pH 5 NaAc buffer. Data is presented as mean ± SE of two independent 
experiments. 
 
2.3.3.  Apparent kinetics of TJ barrier formation determined using the LY Papp assay 
 
The effect of culturing time on LY permeability was detemined to understand the apparent kinetics 
of TJ formation. The mean LY Papp values from day 1 to 10-post seeding are shown in Figure 2-
6a. The mean Papp started as 4.25×10-4 cm/min on Day 1 and slightly decreased to 3.32×10-4 
cm/min on Day 2. The mean Papp value increased to 3.93×10-4 cm/min on Day 3 and fluctuated 
with no significant change until Day 6. The Papp values significantly decreased to 2.36×10-4 
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cm/min on Day 7 comparing to Day 1 (P < 0.05), suggesting that the tight barrier start to form. 
The Papp values stabilized in the range between 2.14×10-4 and 2.36×10-4 cm/min from Day 7 to 
Day 10, which implied the barrier formation was complete, resulting in decreased LY paracellular 
transport. The LY recovery (%) of every time point was higher than 80%, an accepted  standard to 
allow reliable calculation of Papp values [150] (Figure 2-6b).  
 
 
Figure 2-6 a) Apparent kinetics of TJ barrier formation determined using the LY Papp assay. LY 
Papp through hCMEC/D3 monolayers cultured on tissue culture inserts were measured everyday 
post-seeding cells. b) %LY recovered in each treatment group. Data is presented as mean ± SE of 
two independent experiments (n=3/experiment). Statistical comparisons were made using unpaired 
t-test (*P< 0.05, N.S. not significant). 
 
2.3.4.  Western Blot for Detection of Tight Junction Protein ZO-1 
 
Western blot was conducted to detect changes in the expression of the tight junction protein ZO-1 
over time (Figure 2-7a and b). The changes in ZO-1 expression is used to orthogonally confirm 
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the LY Papp data and to ensure that the observed changes in LY Papp is due to the formation of a 
tight barrier. The ZO-1 band intensities were analyzed by densitometry and normalized against the 
expression of a housekeeping gene, glyceraldehyde 3-phosphate dehydrogenase (GAPDH). The 
two bands in Figure 2-7a represent the two ZO-1 isoforms (ZO-1α+ and ZO-1α-) [151]. 
Densitometry analysis revealed that the pixel value of ZO-1 increased from Day 3-7 post-seeding, 
suggesting that the TJ protein ZO-1 formed continually from Day 3-7 (Figure 2-7b). After calcium 
depletion treatment on Day 7 post-seeding, the band of ZO-1 was almost undetectable, which 
indicated that ZO-1 was unable to form in the absence of calcium ions. Moreover, the pixel value 
of ZO-1 markedly decreased at Day 10 post-seeding. The signal intensities of GAPDH from Day 
3-10 were comparable, except on Day 7 when the cells were treated with calcium-free medium. A 
possible reason for the lower GAPDH expression in calcium-treated cells was influenced by 
calcium depletion, leading to lesser total protein (28.9 µg) production.  Overall, the band 
densitometry analysis revealed a gradual increase in ZO-1 expression (relative to GAPDH) in the 
first 7 days and a decrease in expression on Day 10 when cells cultured in complete growth 
medium. The analysis also revealed a lower expression of ZO-1 (relative to GAPDH) on Day 7 in 
cells treated with calcium-free medium. 
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Figure 2-7 a) Apparent kinetics of ZO-1 expression detected using western blotting. b) Band 
densitometry analysis allowed normalizing expression of ZO-1 protein to GAPDH. Data is 
presented as mean ± SE of four independent experiments. 
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2.3.5.  Transfection activity of DNA NPs in hCMEC/D3 monolayers 
 
The relatively low transfection efficiency in the naked DNA-treated cells is typical because the 
anionic nature of plasmid DNA (due to phosphate groups in its backbone) and its hydrophilic 
nature limit cellular uptake. DNA condensed in DNA NP mediated a 50-fold increase in 
transfection compared to naked pDNA (Figure 2-8). Addition of 0.01% P84 to the DNA NP 
resulted in an 18-fold increase compared to pure DNA NP (P< 0.01). Increasing the P84 
concentration to 0.03 wt.% resulted in a 30-fold increase compared to pure DNA NP (P< 0.001).  
 
 
Figure 2-8 DNA NPs mediate high levels of transgene expression in hCMEC/D3 monolayers. 
DNA NP represents that gWIZ Luc pDNA was condensed in PEG-DET at N/P 10; PEG-DET NP 
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+ 0.01% / 0.03% P84 represents that gWIZ Luc pDNA was condensed in PEG-DET at N/P 10 
with 0.01% / 0.03% w/v P84. Data is presented as mean ± SE of three independent experiments. 
Statistical comparisons were made using unpaired t-test (** P< 0.01, *** P< 0.001). 
 
2.3.6.  Effect of DNA NP transfection on LY Papp 
 
While the high levels of transfection was observed in the group of DNA NPs with P84, LY Papp 
through hCMEC/D3 cells 4 h post-transfection was measured to determine whether DNA NP 
transfection perturbed the TJ barrier integrity (Figure 2-9a). The DNA NPs containing P84 mediate 
high levels of gene expression in hCMEC/D3 cell line (Figure 2-9a). Specifically, we wanted to 
determine if the hydrophobic domains of P84 in our DNA NPs may perturb TJ integrity in 
transfected cells. The % LY recovered in each treatment group was ca. 92%, suggesting that the 
calculated Papp values are reliable (Figure 2-9b). The transfection procedure using various 
formulations did not affect the LY Papp, relative to non-transfected cells exposed to LY alone. 
Extracellular calcium is a critical component for the maintenance of cell-cell junctions in various 
cell types [152-154], including the brain microvessel endothelial cells. Thus, maintaining cells in 
calcium-free medium (CFM) leads to the disruption of TJs [155, 156]. Therefore, we used cells 
treated with CFM for 24 h as a positive control.  
 
The LY Papp for cells incubated with CFM was 2-fold higher compared to control cells incubated 
with the regular growth medium. This 100% increase in Papp suggests that the cells lost their TJs 
because of the loss of calcium ions. Notably, the actual value (5.14×10 -4 cm/min) was slightly 
higher than the average Papp value from Day 1-6 post seeding when the TJs were not yet fully 
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formed. Albeit cells transfected with DNA NP containing 0.01-0.03% P84 showed an increase in 
LY Papp values compared to the untreated cells maintained in regular culture medium, the increase 
is not significant. It suggested that transfection of DNA NP with P84 had no significant effect on 
TJ barrier integrity.  
 
 
Figure 2-9 a) Effects of DNA NPs with or without P84 transfection on TJ barrier tightness 
measured using the LY Papp assay. The group of untreated cells was served as negative control. 
The group of 24 h calcium depletion and empty insets with collagen were served as positive control. 
b) %LY recovered in each treatment group. Data is presented as mean ± SE of four independent 
experiments (n=3/experiment). Statistical comparisons were made using unpaired t-test (*P< 0.05). 
 
2.3.7.  Effect of DNA NP transfection on cell viability using Luciferase-Based ATP Assay 
 
The cell viability of cells transfected was measured under different conditions to confirm that the 
transfection procedure does not cause cell stress. Adenosine triphosphate (ATP) is the energy 
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currency of life and reflects cellular metabolic function. Possimo et al. reported that the 
luminescence ATP assay was a robust measure of metabolic cell viability [157]. The cell viability 
of hCMEC/D3 cells transfected by the various formulations was comparable to untreated cells  
(Figure 2-10), suggesting that the ATP levels were similar as well. Therefore, DNA NPs containing 
P84 (0.01% to 0.03% w/w) are safe gene delivery formulations.  
 
 
Figure 2-10 Effect of DNA NPs with 0.01% or 0.03% P84 on hCMEC/D3 monolayers was 
evaluated using a luminescent ATP assay. The hCMEC/D3 cells were cultured for 7 days, then 
transfected with the indicated samples for 4 h following which the ATP assay was conducted by 
manufacturer’s protocol. From left to right: the group of Naked pDNA represents that the cells 
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were not treated with DNA NPs with P84 and served as negative control. DNA NP represents that 
0.5 µg gWIZ Luc pDNA was condensed in PEG-DET at N/P 10; DNA NP + 0.01% P84 represents 
0.5 µg gWIZ Luc pDNA was condensed in PEG-DET at N/P 10 with 0.01% P84; DNA NP + 
0.03% P84 represents 0.5 µg gWIZ Luc pDNA was condensed in PEG-DET at N/P 10 with 0.03% 
P84. Data is presented as mean ± SE of two independent experiments (n=3/experiment). Statistical 
comparisons were made using one-way ANOVA. 
 
2.3.8.  The amount secretion of BDNF transfected hCMEC/D3 cell via BDNF DNA NPs 
 
The amount secretion of BDNF protein was measured by the protocol of the BDNF Emax® 
Immuno assay. Compared to untreated cells, the BDNF expression in the group of DNA NPs with 
0.03% P84 and lipo 3000 (positive control) did not significantly increase (Figure 2-11). In order 
to understand if the P84 and BDNF pDNA affected the BDNF expression, a 2 level 2 factor full 
factorial design (Table 2-2) was conducted to investigate the influence of the concentration of P84 
and amount of BDNF pDNA. The transfection procedure using various formulations did not 
increase the expression of BDNF, compared to untreated cells (Figure 2-11).  
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Figure 2-11 DNA NPs with P84 could not increase the secretion of BDNF in hCMEC/D3 
monolayers. From left to right: the group of control, untreated cells represent that the cells were 
not treated with DNA NPs with P84 and served as negative control. N/P 10 + 0.03% + 0.5 µg 
represents that 0.5 µg gWIZ Luc pDNA was condensed in PEG-DET at N/P 10 with 0.03% P84; 
N/P 10 + 0.06% + 0.5 µg represents that 0.5 µg gWIZ Luc pDNA was condensed in PEG-DET at 
N/P 10 with 0.06% 84; N/P 10 + 0.03% + 2 µg represents that 2 µg gWIZ Luc pDNA was 
condensed in PEG-DET at N/P 10 with 0.03% P84; N/P 10 + 0.06% + 2 µg represents that 2 µg 
gWIZ Luc pDNA was condensed in PEG-DET at N/P 10 with 0.06% P84.The Lipo 3000 + 0.5 µg 
represents that 0.5 µg gWIZ Luc pDNA was mixed with lipofectamine 3000. Data is presented as 
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mean ± SE of two independent experiments (n=3/experiment). Statistical comparisons were made 
using one-way ANOVA. 
 
2.3.  Discussion  
 
Three key perspectives will be discussed in this chapter. They are listed as follows: 
 
1) Formulation development including formation of DNA NPs and formulation optimization; 
2) Characterization of transfection efficiency and cytocompatibility of DNA NPs to the TJ 
Integrity; 
3) Transfection of BDNF DNA NPs with 0.03% P84. 
 
2.3.1.  Formulation development 
 
The ability of PEG-DET to combine with DNA was confirmed by gel retardation and EtBr 
exclusion assay. The presence of band in the gel retardation and strong fluorescence in the EtBr 
exclusion assay indicated the free DNA or loosened PEG-DET/DNA complexes. After the addition 
of PEG-DET, the DNA band disappeared, and fluorescence became weak. Those phenomena can 
be attributed to PEG-DET, which condensed DNA to form DNA NPs and dislocated the 
intercalated EtBr from DNA [158].  
 
The DNA NPs formulation was characterized in terms of particle size and surface charge. The 
particle size is closely associated with the cell uptake, and the surface charge influences the 
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efficiency of DNA condensation and interaction with cells [159]. Particle size and zeta potential 
of DNA NPs were measured and listed in Figure 2-5. It demonstrated that the PEG-DET resulted 
in significant size reduction and surface charge increase. When DNA NPs with an N/P ratio of 10, 
the particle size was 83.2 ± 1.0 nm with a narrow PdI (0.17 ± 0.01). Measurements of the zeta 
potential showed that the surface charge was affected by the addition of PEG-DET, and indicated 
that the increase in the surface charge resulted by increasing concentration of positively charged 
PEG-DET. The positive charge (8.3 ± 0.3 mV) of N/P 10 facilitated the interaction between DNA 
NPs and cells. Thus, the ratio of N/P 10 was chosen for future transfection experiments. 
 
2.3.2.  Characterization of transfection efficiency and cytocompatibility 
 
Transfection efficiency and cytotoxicity are the most important parameters in gene delivery 
systems [160]. PEG-DET is an attractive candidate for non-viral gene therapy due to its high 
transfection activity and low cytotoxicity [83]. Ethylenediamine (DET) is the side chain of PEG-
DET, which is expected to provide an effective buffering function in the acidic endosomal 
compartment and cause an increase in osmotic pressure in the endosome, leading to the disruption  
of the endosomal membrane for the enhancement of DNA escape from the  endosomal 
compartment [83, 161]. 
 
The transfection efficiency of DNA NPs was measured using luciferase as a model plasmid. The 
DNA NPs mediated significant levels of gene expression in the hCMEC/D3 monolayers [133, 162-
164], compared to naked pDNA alone. To further increase both cellular uptake and nuclear 
transport of pDNA delivered into cells with DNA NPs, P84 was added in the DNA formulation. 
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Several studies reported that Pluronic bound to cell membranes and activated NFκB signaling 
pathway, which lead NFκB to contact with cytosolic pDNA that contained NFκB binding sites, to 
enhance nuclear import of pDNA [76, 93]. The results shown in Figure 2-8 indicated that DNA 
NPs containing 0.01 or 0.03% P84 increased luciferase gene expression by 18-and 30-fold, 
respectively, compared to pure DNA NPs. The Pluronic block copolymer was demonstrated to 
enhance nuclear gene transfer with polyplex-delivered pDNA.  
 
However, Pluronic has also been reported to influence the permeability of cells [18, 36]. If the 
0.03% P84 damaged the TJ integrity and increased the permeability of cells, the inflammation 
factors such as leukocytes would enter brain along with blood flow and result secondary brain 
injury. Thus, in order to examine the cytocompatibility of DNA NPs with 0.03% P84 to the TJ 
integrity, LY Papp assay was developed to determine the confluent monolayer formation in cultured 
hCMEC/D3 cells. Although other advanced in vitro BBB systems, such as co-culture systems, 
microfluidic systems are physiologically relevant mimics with improved barrier function [165-
167], the hCMEC/D3 culture insert setup is  a simple and reliable mode to estimate the kinetics of 
TJ formation and rapidly screen the effect of different drug formulations on barrier function. In 
our experimental setup, the brain endothelial cells are seeded on a collagen-coated microporous 
membrane for cell attachment and monolayer formation to mimic the in vivo barrier. The LY added 
in the apical side is expected to traverse the intercellular tight junctions and accumulate in the 
basolateral side. Greater concentration of LY in the basolateral side indicate an immature, not-
fully functional barrier while lower concentration reflects restricted transport due to the presence 
of functional TJs resulting in a mature barrier. Recovery% is an important index in LY assay. For 
example, if cells metabolize most LY, LY is immobilized in cells or sticks to the cell membrane 
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or LY degrades during incubation, it would be inaccurate to interpret that observed low LY signal 
in basolateral compartment indicates a tight barrier. Thus, recovery% gives more confidence that 
we did not lose significant amount of LY owing to one or more of the above possibilities and 
allowes to confidently estimate LY Papp values. As noted earlier in the introduction section, greater 
concentrations of LY in the basolateral side indicates an incomplete barrier while lower 
concentrations reflect restricted transport, suggesting a mature, complete barrier due to the 
presence of functional TJs.  
 
We demonstrated a LY Papp assay as a quantitative method to determine the kinetics of tight 
junction barrier formation in a human cell model of the BBB. The expression of ZO-1 also detected 
via western blotting orthogonally validated the data from the LY Papp studies. As the utility of the 
developed assay, the DNA NP transfection in hCMEC/D3 monolayers does not affect the integrity 
of TJs (Figure 2-9a). Untreated cells incubated with growth medium was used as the negative 
control and cells pre-incubated with calcium free medium for 24 h was used as a positive control. 
Cells in which the TJs were disrupted as a result of the calcium depletion showed a 210% increase 
in LY Papp compared to the untreated cells. It is noteworthy that LY Papp value generated from a 
confluent hCMEC/D3 monolayer was approximately 50% compared to the negative control (cells 
exposed to calcium-free medium), suggesting a limitation in using hCMEC/D3 cell line as a BBB 
cell model. The data suggests that DNA NP transfection either in the presence or absence of 0.01% 
or 0.03% P84 does not affect the TJ integrity. It should be noted that the lack of LY Papp changes 
in transfected cells is not an inconsequential observation. A potential cytotoxic effect of DNA NPs 
with P84 was investigated in hCMEC/D3 monolayers using the luciferase-based ATP assay. It 
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revealed that DNA NPs with P84 did not adversely affect the cellular ATP levels, used here as an 
indicator of functional cell viability (Figure 2-10).  
 
2.3.3.  Transfection of BDNF pDNA NPs with 0.03% P84 
 
Although PEG-DET with P84 safely delivered Luc pDNA into the hCMEC/D3 cells and resulted 
in high luciferase transfection levels, the same formulation did not improve the secretion of BDNF, 
compared to untreated cells. Even at a higher concentration of P84 (0.06% w/v) and BDNF DNA 
(2 µg/well), the secretion of BDNF did not increase. There could be three potential reasons that 
led to these results (Figure 2-12). The first reason is that the insufficient BDNF DNA entered the 
nucleus. However, we observed that PEG-DET with P84 significantly increased luciferase 
expression. Thus, a second reason was proposed. The BDNF DNA might be successfully delivered 
into nucleus but could not be transcribed and translated to BDNF protein. Unlike the extraneously 
introduced Luc pDNA, BDNF gene is present in the hCMEC/D3 cells and its expression might be 
tightly controlled by brain endothelial cells. Although there are no published papers about strict 
BDNF regulation by hCMEC/D3 cells, Herzog et al. reported that the expression of BDNF was 
strictly regulated in the chick visual system [168]. Hence, even with successful delivery of extra 
BDNF DNA into nucleus, the BDNF expression might not increase in hCMEC/D3 cells. The third 
reason is that the extra BDNF protein might be produced inside the cells but was not secreted into 
extracellular environment. In the experiment of luciferase gene expression, the transfected cells 
were lysed, then the luciferase expression in the cell lysates was measured. Accordingly, the extra 
BDNF might produce within cells after transfection of BDNF DNA with P84, but only limited 
amount BDNF was secreted from cells. 
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Figure 2-12 Three proposed mechanisms to explain the lack of BDNF secretion after BDNF DNA 
NPs transfection. 1) Not enough BDNF DNA might have entered the nucleus; 2) The BDNF DNA 
might be successfully delivered into nucleus but could not be transcribed and translated to BDNF 
protein; 3) The extra BDNF DNA might be delivered into nucleus, and cells could produce extra 
BDNF within the cells, but did not secrete into extracellular environment. 
 
2.4.  Conclusion  
 
We concluded DNA NPs with 0.03% P84 was a promising formulation to deliver Luc pDNA into 
hCMEC/D3 cells safely and efficiently. Moreover, to ensure the safety of the formulation on the 
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integrity of TJs, a LY Papp method was developed to quantify the paracellular permeability across 
hCMEC/D3 cell monolayers.  By using LY Papp method, we optimized the culture time for the 
formation of intact barrier, and we demonstrated the utility of the developed assay to determine TJ 
integrity in DNA NP-transfected cell monolayers. However, the formulation did not result in high 
levels of BDNF secretion, compared to untreated cells. Thus, further understanding of the reasons 
for the lack of extra BDNF secretion after transfection of BDNF DNA NPs with P84 is necessary 
for the next design of novel gene transfer carriers of BDNF DNA delivery. Other non-viral carriers 
were explored for delivering BDNF DNA in an in vitro BBB model. Extracellular vesicles derived 
from cells share similar lipids rafts and membrane protein with parent cells [100]. Hood et al 
reported that extracellular vesicles had an intrinsic ability to target on the same cell species [110]. 
Therefore, compared to transfection efficiency of engineered polymers, biological carriers 
(extracellular vesicles) may have a potential to improve the gene delivery and advance the cell 
survival. 
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Chapter 3: Gene Delivery via Extracellular Vesicles in a Human 
BBB Model 
 
3.1.  Introduction  
 
Extracellular vesicles (EVs) are generated by cells and secreted to the extracellular environment. 
EVs are released by almost all cell types [169]. Based on their particle diameters, EVs can be 
divided into three categories: 1) exosomes with diameters ranging from 30-150 nm, 2) 
microvesicles (MVs) with diameters ranging from 100-1000 nm and  3) apoptotic bodies with 
diameters ranging from 500-5000 nm ) [96]. 
 
 The tPA is the only drug approved for the treatment of stroke. The role of tPA is to catalyze the 
plasminogen to plasmin, which is the major enzyme responsible for clot breakdown. However, the 
plasminogen activator lacks the ability to enhance recovery while neurological deficits persist. A 
regenerative therapy is in high demand [1]. Many published papers have reported that exosomes 
can function as a regenerative tool to treat neurological diseases. Xin et al reported that EXOs 
contain multiple functional mRNAs, micro RNAs (miRNAs) and proteins that promoted 
functional recovery and neurovascular plasticity after stroke in rats [170]. 
 
Microvesicles share some roles of EXOs [108]. For example, mesenchymal stem cells (MSCs) 
derived-MVs reduced inflammation, enhanced angiogenesis, and increased endogenous 
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neurogenesis in the rat brain. Moreover, MVs have some unique features and contain mitochondria 
and mitochondrial DNA (mtDNA) [115, 116]. Phinney et al reported that MV derived from MSCs 
mediated mitochondrial transport and advanced macrophage function by improving mitochondrial 
bioenergetics. Besides, Webb et al. showed that intravenous administration of a combination of 
EXOs and MVs from neural stem cell–derived (NSC) EVs significantly improved tissue and 
functional level outcomes in a translational pig ischemic stroke model [107]. Therefore, EVs are 
promising class of therapeutics of addressing the need for a neuroprotection and regeneration.  
 
Kanada et al reported that MVs delivered pDNA in recipient cells and induced the subsequent 
expression of encoded reporter proteins such as luciferase [118]. In addition, the presence of 
double-stranded DNA was verified in EXOs using Quantifluor dsDNA detection method and 
atomic force microscopy (AFM) [171]. Our goal is to deliver brain-derived neurotrophic factor 
(BDNF) that has been reported to increase the chance of neuronal survival after stroke [126]. 
Several evidences indicate that BDNF prevented cell death and promoted neuronal function in 
animal models of CNS diseases [58].  For example, BDNF protein significantly decreased 
apoptotic percentage of serum deprivation cell model and reduced the infarct area in middle 
cerebral artery occlusion (MCAO) model [61]. Moreover, intravenous infusion of BDNF showed 
the behavioral improvement such as total distance travel and movement time in stroke rats [127]. 
Thus, we propose to use EXOs and MVs to deliver BDNF DNA to treat ischemic stroke.  
 
Exosomes have an intrinsic ability to home targets depending on their cell sources [110]. Thus, 
EXOs and MVs derived from hCMEC/D3 cells had affinity to the same cell species and increase 
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gene delivery efficiency. After collecting exosomes from hCMEC/D3 cell from parent hCMEC/D3 
cells which were transfected by lipofectamine 3000/BDNF DNA complexes, the BDNF DNA-
containing EXOs and MVs were used to treat the receptor hCMEC/D3 cells. The transfection 
efficiency of BDNF DNA via hCMEC/D3-derived EXOs and MVs may be superior compared to 
synthetic polymers.  
 
Specific hypothesis: We hypothesized that extracellular vesicles (e.g., EXOs and MVs) isolated 
from hCMEC/D3 transfected cells with BDNF pDNA, will increase the ATP level in hCMEC/D3 
monolayers.  
 
3.2.  Materials and Methods 
 
3.2.1.  Materials 
 
The following materials were procured from the respective suppliers indicated in parentheses. 
hCMEC/D3 cell line (Cat# 102114.3C-P25, Cedarlane Laboratories); Collagen Type I (Cat# 
354236, Discovery Labware, Inc); Endothelial cell basal medium-2 (EBM-2, Cat# CC-3156, 
Clonetics); Plasmid DNA encoding luciferase gene, gWiz-Luc (Cat# 5000-500, Aldevron); 
Plasmid DNA encoding BDNF, gWiz-BDNF (Cat# 88282, Aldevron); 0.22-μm Sterile Syringe 
Filters (Cat# 09-720-004, Fisher scientific); Micro BCA Protein Assay Kit (Cat# 23235, Thermo 
Scientific); Pierce BCA Protein Assay Kit (Cat# 23225, Thermo Scientific); Lipofectamine™ 
3000 Transfection Reagent (Cat# L3000015, Invitrogen); Laemmli SDS sample buffer (Cat# 
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J60015, Alfa Aesar, MA); Odyssey® Blocking buffer in PBS (Cat# 927-40000, Li-Cor);  Quant-
it PicoGreen Assay kit (cat# P7589, Life Technologies); Mouse monoclonal antibody to GRP94 
(Cat# sc-393402, Santa Cruz Biotechnology, Inc); Mouse monoclonal antibody to ATP5A (Cat# 
ab14748, abcam), Mouse monoclonal antibody to GAPDH (Cat# ab8245, abcam); Mouse 
monoclonal antibody to Alix (Cat# sc-53540, Santa Cruz Biotechnology, Inc); Mouse monoclonal 
antibody to CD9 (Cat# 10626D, Life Technologies Corporation); Donkey Anti-mouse IgG, Alexa 
Fluor® 790 (cat# 715-655-150, Jackson ImmunoResearch Lab Inc.); Cell TiterGlo Luminscent 
Cell viability assay (Cat# G7572, Promega). 
 
3.2.2.  Methods 
 
3.2.2.1.  Cell Culture 
 
The hCMEC/D3 cells were cultured in complete hCMEC/D3 cell medium supplemented with 
EBM-2 endothelial basal medium, 5% fetal bovine serum (FBS), 1% penicillin streptomycin, 1.4 
µM hydrocortisone, 5 µg/mL acid ascorbic, 1/100 chemically defined lipid concentrate, 10 mM 
HEPES, 1 ng/mL bFGF, and incubated at 37 °C in a 5% CO2 atmosphere. 
 
3.2.2.2.  EVs Isolation from hCMEC/D3 Cells 
 
To isolate EVs (EXOs and MVs in this case), hCMEC/D3 cells were seeded in collagen-coated 
175 cm2 flasks and cultivated for 3 d or until ~70% confluency [172]. Growth medium was then 
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removed, and cells were washed with 25 mL pre-warmed 1× PBS and cultured in 25 mL FBS-free 
(serum-free) medium for 2 d. The EXOs and MVs were harvested using a sequential centrifugation 
method with slight modifications [115, 118, 172]. Conditioned medium is defined as the FBS-free 
medium that cultured cells for 2 d. Briefly, conditioned medium from 175 cm2 flasks were 
centrifuged at 300×g for 10 min at 4 °C to remove dead cells and debris (Dupont RC5C Centrifuge). 
Supernatants were carefully transferred into new tubes and centrifuged at 2,000 × g for 20 min at 
4 °C to remove large vesicles such as apoptotic bodies. Afterwards, the supernatant was 
centrifuged at 20,000 × g for 45 min at 4 °C to pellet MVs using an XE-90 Ultracentrifuge fitted 
with a 50.2Ti rotor (Beckman Coulter). The collected supernatant was then pressure-filtered 
through 0.22-μm membrane filters to remove vesicles larger than 220 nm in diameter. Finally, 
EXOs were collected by ultracentrifugation at 120,000 × g for 70 min using an Optima XL-90 
Ultracentrifuge fitted with a 50.2Ti rotor (Beckman Coulter). Isolated EVs were quantified by 
measuring their total protein concentration using Pierce BCA protein assay kit and micro BCA 
protein assay kit. In the last step, EVs were suspended in 1x RIPA buffer up to a final volume of 
150-200 µL for western blot, 10 mM HEPES buffer for zeta potential measurement, and 1 × PBS 
for all other experiments. The EV suspensions were stored at −80 °C. 
 
3.2.2.3.  DNA Loading in EVs 
 
To load gWIZ-Luc pDNA and BDNF pDNA into EVs, hCMEC/D3 cells were transfected with 
pDNA using Lipofectamine 3000 transfection reagent using a modified transfection protocol to 
decrease lipied-mediated cytotoxicity. Briefly, the donor cells were seeded in 24-well plates at a 
cell density of 75,000 cells/cm2 and cultured for 2 d or until ~70% confluent. Then, the cells were 
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transfected by Lipofectamine 3000/pDNA complexes with 0, 0.5 and 1 µg/well of pDNA in 
complete hCMEC/D3 cell medium for 12 h. Afterwards, the transfection medium was removed, 
and the cells were washed by 1× PBS, followed by culturing with serum-free medium for 2 d. The 
supernatant from each well was transferred into a tube for EV isolation.  
 
3.2.2.4.  Characterization of EVs 
 
The total protein content in exosomes and MVs were quantified by MicroBCA. Then, 0.72 mg/mL 
EXOs and MVs were measured in a DLS for determining intensity-weighted z-average diameter, 
PdI, and zeta potential. The size was measured in 1 × PBS, and the zeta-potential was measured in 
10 mM HEPES at 25°C with 90.0 scattering angle using a Malvern Zetasizer Nano ZS90 (Malvern, 
UK). Three replicates were conducted for each measurement. 
 
3.2.2.5.  Protein composition and EV markers using western blot 
The hCMEC/D3 cells and EVs derived from hCMEC/D3 cells were lysed with 1x RIPA buffer 
mixed with aprotinin (0.003 mg/mL). Then, the lysates were quantified by BCA assay, then mixed 
with 4x Laemmli buffer and kept at 95°C for 5 min. Samples containing 25 µg total protein were 
separated on a 4-10% gradient SDS-PAGE gel and transferred to a nitrocellulose membrane. CD9, 
ATP5A, GRP94 and GAPDH antibodies were applied for protein detection. Primary and 
secondary antibodies were diluted 200 - 30,000- fold in 0.5 × blocking buffer. Final gel images 
were obtained using a 16-bit Odyssey imager. 
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3.2.2.6.  DNA Quantification using Quant-it PicoGreen Assay kit 
 
PicoGreen assay was used to quantify the amount of double stranded DNA (dsDNA) in EXOs and 
MVs. PicoGreen is a DNA-binding benzothiazole dye. The dye is a fluorescent sensor that 
specifically binds to dsDNA, and minimizes the effect of RNA and single-stranded DNA (ssDNA) 
on the results [173]. The fluorescence emission was proportional to DNA concentration. Cells 
were either transfected using 0, 0.5 and 1 µg/well luc pDNA complexed with Lipofectamine, then 
the luc pDNA-containing EVs were collected. The Luc pDNA-containing EVs were lysed by 
RIPA buffer and the final volume of lysates were between 100-300 µL. Following the 
manufacturer’s protocol, the mixture of sample and working reagents was prepared at the ratio of 
1:1 (100 µL sample + 100 µL Picogreen reagent). The fluorescence was measured via a plate 
reader (Synergy 2 Multi-Detection Microplate Reader, BioTek) (excitation: 485 nm, emission: 528 
nm), and DNA loading (%) was calculated by the following equation 3-1. 
 
𝐷𝑁𝐴 𝐿𝑜𝑎𝑑𝑖𝑛𝑔 (%) =  
(𝑇𝑜𝑡𝑎𝑙 𝐷𝑁𝐴 𝑖𝑛 𝑝𝐷𝑁𝐴 𝑐𝑜𝑛𝑡𝑎𝑖𝑛𝑖𝑛𝑔 𝐸𝑉𝑠 −𝑇𝑜𝑡𝑎𝑙 𝐷𝑁𝐴 𝑖𝑛 𝑒𝑚𝑝𝑡𝑦 𝐸𝑉𝑠)
𝑇𝑜𝑡𝑎𝑙 𝐷𝑁𝐴  𝑡𝑟𝑎𝑛𝑠𝑓𝑒𝑐𝑡𝑒𝑑 𝑖𝑛𝑡𝑜 𝑡ℎ𝑒 𝑐𝑒𝑙𝑙𝑠 𝑢𝑠𝑖𝑛𝑔 𝐿𝑖𝑝𝑜𝑓𝑎𝑐𝑡𝑚𝑖𝑛𝑒 3000
× 100%     Eq. 3-1                         
 
3.2.2.7.  The transfer of Luc pDNA-containing EVs to Cells 
 
Luc pDNA (0, 0.5 and 1 µg/well) were transfected into donor hCMEC/D3 cells via lipofectamine 
3000. Then, Luc pDNA - containing EXOs and MVs were collected from 24-well plates. 
Afterwards, the EXOs and MVs were quantified by MicroBCA assay.  
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The receptor hCMEC/D3 cells were seeded with the density of 50,000 cell/cm2 in a 48-well plate 
and cultured for 2 days in the incubator (37°C, 5% CO2). Then, the growth medium was removed 
and replaced with a mixture of 250 µL cell culture medium and Luc pDNA-containing EXOs or 
MVs with 6 µg or 12 µg total EV protein (Table 3-1). The receptor cells were cultured for 
additional 24 or 48 h (incubation time). Then, the mixture solution of culture medium and pDNA-
containing EVs was removed, and the receptor cells were washed with cold 1X PBS buffer and 
lysed by ice-cold luciferase cell culture lysis 1X reagent. Finally, the luciferase gene expression  
and total protein of receptor cell lysates were measured using a BioTek plate reader. 
 
The effect of the incubation time, DNA transfected into cells, type of carriers and total EV protein 
on the transfection efficiency of pDNA - containing MVs and EXOs were evaluated using a 
factorial design shown in Table 3-1. The design required a total of 24 experiments, 9 replicates for 
each design point. Each factor, the lower and higher values of the lower and upper levels, was 
represented by a (− 1) and a (+ 1) and the central point was represented by (0). The data were 
analyzed using JMP Pro 14. 
 
Table 3-1 The DNA transfected into cells represents the amount of luc pDNA transfected into 
donor cells via lipofectamine3000; The total EV protein represents the total amount of EXOs or 
MVs quantified by micro BCA protein assay; Incubation time represented that  the time that 
receptor cells were treated using luc pDNA-containing EVs. N/A: not applicable.  
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Factors  Level (-1) Level (0) Level (+1) 
DNA transfected into 
cells 
0µg/well luc 
pDNA 
0.5 µg/well luc 
pDNA 
1 µg/well luc 
pDNA 
Total EV protein 6µg N/A 12 µg 
Type of carriers EXOs N/A MVs 
Incubation time 24 hours N/A 48 hours 
 
3.2.2.8.  The influence of BDNF pDNA-containing EVs on the ATP levels in receptor 
hCMEC/D3 Cells 
 
A certain amount of BDNF pDNA (0, 0.5 and 1 µg/well) were transfected into donor hCMEC/D3 
cells with lipofectamine3000 (Figure 3-1). Afterwards, BDNF pDNA – containing EVs were 
collected from 24-well plates. Then, the protein content in EXOs and MVs were quantified by 
MicroBCA assay.  
 
The receptor hCMEC/D3 cells were seeded with the density of 5,000 cell/cm2 in a 96 well plate 
and cultured for 3 days in the incubator (37°C, 5% CO2). The growth medium was removed and 
replaced with a mixture of 100 µL cell culture medium and BDNF pDNA-containing EXOs or 
MVs with 6 µg or 12 µg total EV protein (Table 3-2). The receptor hCMEC/D3 cells were cultured 
for another 24 or 48 h. The mixture solution of culture medium and BDNF pDNA-containing EVs 
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was then removed. The wells were gently washed with pre-warmed 1X PBS buffer. The 
luminescence was measured by a Tekplate reader, and the relative ATP level (%) was calculated 
using the following equation:  
 
Relative ATP level (%) = 
𝐿𝑢𝑚𝑖𝑛𝑒𝑠𝑐𝑒𝑛𝑐𝑒 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑤𝑖𝑡ℎ 𝐸𝑉𝑠
𝐿𝑢𝑚𝑖𝑛𝑒𝑠𝑐𝑒𝑛𝑐𝑒 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑤𝑖𝑡ℎ 1X PBS buffer 
× 100                       Eq.3-2              
Equation 3-5 Formulae for the percentage of the cell viability. The luminescence of cells treated 
with EVs represents that the light was emitted from cell lysate that was treated with EVs; The 
luminescence of cells treated with 1X PBS buffer represents that the light was emitted from cell 
lysate that was treated with 1X PBS buffer.  
 
The influence of the incubation time, DNA transfected into cells and total EV protein on the ATP 
production of BDNF pDNA - containing MVs and EXOs, which were evaluated using a factorial 
experimental design. The design included a total of 18 experiments with 4 replicates for each 
experiment and 12 replicates of growth medium and PBS buffer mixture for blank control. In each 
experimental point, before inputting the experimental treatment, 100 µL growth medium was 
added into wells. For the design factor, the lower and higher values of the lower and upper levels, 
was represented by a (− 1) and a (+ 1) and the central point was represented by (0) as summarized 
in Table 3-2. In the case of isolated EXOs and MVs, the level -1 represents 6 µg protein and the 
level 1 represents 12 µg protein. While in the design point of the EXO and MV combination, the 
level -1 represents 3 µg EXOs and 3 µg MVs (in total 6 µg protein) and the level 1 represents 6 
µg EXOs and 6 µg MVs (in total 12 µg protein). The results were analyzed using JMP Pro 14. 
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Table 3-2 The DNA transfected into cells represented that certain amount of BDNF pDNA 
transfected donor cells via lipofectamine3000; The total EV’s protein represented that certain 
amount of EXOs or MVs were quantified by total protein which was measured by micro BCA 
protein assay; N/A: not applicable. 
Factors  Level (-1) Level (0) Level (+1) 
DNA transfected into cells 0 µg BDNF pDNA 0.5 µg BDNF 
pDNA 
1 µg BDNF pDNA 
Total EV protein 6 µg EXOs/MVs or 
3 µg EXOs +3 µg 
MVs 
N/A 12 µg EXOs/MVs or 
6 µg EXOs +6 µg 
MVs 
Type of carriers EXOs EXOs+MVs MVs 
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Figure 3-1 hCMEC/D3 cells were transfected using Lipo/BDNF pDNA complexes, then secreted 
BDNF pDNA - containing MVs and EXOs. 
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3.2.2.9.  Statistics 
 
JMP Pro 14 was used to perform all statistical analysis. Multiple regression analysis was used for 
contrast of multiple groups. Statistically significant differences were marked with asterisks (# P < 
0.05, * P < 0.0001 compared to other groups). 
 
3.3.  Results and Discussion 
 
3.3.1.  Isolation and Characterization of EVs 
 
We isolated EXOs and MVs from conditioned medium of hCMEC/D3 cells by differential 
ultracentrifugation (Figure 3-2a). The EXOs and MVs are different in terms of their particle size 
and molecular compositions. The results revealed that differential centrifugation separated EXOs 
and MVs efficiently. In Figure 3-2c, the reported values of the particle size and zeta potential of 
EXOs and MVs were consistent with published results [115, 172, 174]. The average particle size 
of EXOs was 132.4 ± 12.8 nm, with a PdI of 0.27 ± 0.04, whereas MVs appeared to have a larger 
particle size (394.6 ± 19.1 nm) and higher dispersity index (0.41 ± 0.06 nm). Both EXOs and MVs 
were negatively charged (zeta potential of EXOs: -10.3 ± 1.1 mV, MVs: -11.9 ± 2.2 mV) in 10 
mM HEPES, pH 7.4. It is noteworthy that the particle size distributions of EXOs and MVs 
overlapped, indicating that particle size should not be used as the only characteristic to distinguish 
EXOs and MVs. Western blot was conducted to further characterize the two distinct EV 
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populations (Figure 3-2b). Alix and tetraspanins CD9 are commonly used as exosomal markers 
[175] because two types of protein relatively enriched in EXOs but absent in MVs. The western 
blot results showed Alix and CD9 was present in EXO sample but was hardly seen in the MV 
sample (Figure 3-2b). In contrast, ATP5A, a subunit of mitochondrial ATP synthase, is utilized as 
mitochondrial marker for MVs [115, 116]. The western blot results confirmed that ATP5A was 
present in MVs but not in EXOs (Figure 3-2b). GRP94 which was reported as a MV marker [115], 
was not seen in the image of western blot between at molecular weights ranging from 75 to 100 
kD. The difference between published report of Dozio et al [115] and our data may be caused by 
differences in cell culture methods or the primary GRP94 antibody we used. Besides, the 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH), which is typically used as an internal 
control for cellular proteins in many tissues and cell studies, was used as reference in our studies. 
The expression of GAPDH was lower in the EXOs than the MVs, which contradicted  reported 
data [118, 172]. The difference in GAPDH is likely because of the cell line we studied (hCMEC/D3) 
is different from the RAW 264.7 and HEK293FT cells that were reported [118, 172].  
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Figure 3-2 Characterization of EVs. a) Schematic depiction of the isolation protocol for EXOs and 
MVs; b) Western blot analysis of EV markers: Alix, GRP94, ATP5A, CD9. The expression of 
GAPDH was served as reference. c) Z-Average article diameter of EXOs and MVs measured by 
DLS; d) Size distribution plots of EXOs and MVs measured by DLS. Data is presented as mean ± 
SE of two independent experiments. 
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3.3.2.  The extent of Luc pDNA loading 
 
This section investigates the Luc pDNA loading in EXOs and MVs derived from transfected cells. 
Shown in Figure 3-3a, three doses of Luc pDNA (0, 0.5 and 1 µg/well) were transfected into the 
corresponding groups of hCMEC/D3 cells via lipofectamine 3000. DNA loading efficiency in 
EXOs and MVs was quantified using Quant-IT PicoGreen assay. The results showed that EXOs 
contained 381.6 ± 42 ng Luc pDNA in the group of 0 µg/well, 480.8 ± 69.9 ng Luc pDNA in the 
group of 0.5 µg/well and 390.8 ± 46.9 ng Luc pDNA in the group of 1 µg/well, which were 
significantly higher than MVs (0 µg/well: 33.6 ± 1.8 ng, 0.5 µg/well: 60.0 ± 7.4 ng, 1 µg/well: 
81.5 ± 5.5 ng).  It contradicts the report from Kanada and coworker claiming only MVs, but not 
EXOs, could load exogenous pDNA [118]. A possible explanation is that extracellular DNA in the 
conditioned medium was pelleted with EXOs at 120,000 × g centrifugation and was afterwards 
detected by PicoGreen assay. Those extracellular DNA might be released from dead and dying 
cells [176]. Since the transfected cells were cultured in FBS-free medium, some cells might 
undergo apoptosis and necrosis due to lack of nutrition [177] releasing DNA fragments into the 
medium. We speculate this may be the reason that EXOs contained more Luc pDNA than MVs in 
our results. Another possibility is that our study used a different cell type (hCMEC/D3 cells) while 
Kanada et al used HEK293FT cells. 
 
No significant difference (α = 0.05) was observed in DNA concentration among the three 
transfection groups of EXOs and MVs. Meanwhile, overall DNA loading efficiency in these 
experiments was limited to ~2% (measurements were corrected by background signal from the 
group that 0 µg/well DNA was transfected into cells via lipofectamine 3000) (Figure 3-3b). 
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Although 0.5 and 1 µg/well DNA transfected into cells via lipofectamine 3000, not all the 
exogenous DNA entered the cells. Among the amount of DNA that entered the cells, some of them 
would be degraded by lysosomes or be delivered into the nuclei. Only a limited amount of DNA 
was packaged in EXOs and MVs and secreted into extracellular environment. Thus, it might be 
the reason that the DNA loading efficiency in Figure 3-3b was very low. There was no significant 
difference in the total EV protein among all three groups, which indicates that the concentration 
of lipofectamine 3000 used for transfecting 0.5 and 1 µg DNA had no influence on the total EV 
protein. Comparing EXOs and MVs in each DNA level, the total protein content of EXOs was 
similar to MVs, which indicates that total protein of EXOs or MVs was not influenced by different 
level of DNA transfected into cells.   
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Figure 3-3 DNA loading efficiency and measurements of total protein of EXOs and MVs. a) 
transfected hCMEC/D3-derived EXOs and MV were loaded with Luc pDNA via lipofectamine 
3000. DNA in isolated EVs was detected by PicoGreen assay and showed for following groups 
(bars from left to right): EXOs and MVs derived from transfected cells contained Luc pDNA, 
which the transfected cells were treated by lipofectamine 3000/Luc pDNA with 0, 0.5,  1 µg/well. 
b) Evaluation of DNA loading efficiency. All data were corrected by the background signal 
generated of the group (0 µg/well pDNA transfected into cells) into cells. Blue bar represents 
EXOs and red bar represents MVs. c) EXO and MV protein in lipofectamine 3000 transfection 
  
76 
with different amount of luc pDNA (0, 0.5, 1 µg/well). Blue bar represents EXOs and red bar 
represents MVs. Data is presented as mean ± SE of four independent experiments 
(n=3/experiment). Statistical comparisons were made using multiple regression analysis (* P < 
0.0001 compared to other groups). 
 
3.3.3.  Transfection efficiency of Luc pDNA - containing MVs and EXOs 
 
The capability of EVs to deliver nucleic acids (Luc pDNA) was evaluated. The EXOs and MVs 
were collected from the donor hCMEC/D3 cells which was transfected by Luc pDNA, and were 
added to the receptor hCMEC/D3 cells. The receptor hCMEC/D3 cells were expected to produce 
luciferase if the EVs contained DNA and successfully delivered DNA into those cells. 
Luminescence from luciferase was measured by a BioTek plate reader to reflect the transfection 
efficiency of the EVs.  
 
The transfection efficiency was showed in Figure 3-4a. The PBS buffer served as a negative control, 
in which no transfection reagent was involved. The Luc pDNA -containing EXOs and MVs did 
not have higher luciferase expression than the negative control in both 24 and 48 h incubation. 
There are two possible reasons leading to this result: 1) low transfection efficiency of EVs and 2) 
low DNA loading in EVs. The positive control (Lipo 3000, 10 ng), which was transfected by 
lipofectamine 3000 with Luc pDNA (10 ng) to DNA loading in EVs (Figure 3-4b) showed higher 
Lum/total protein than all other groups at 24 h incubation. It indicated that EXOs and MVs had 
lower transfection efficiency than lipofectamine 3000. Interestingly, the positive control group had 
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similar lum/total protein as other groups after 48 h transfection. It is probably due to luciferase 
degradation by proteasome [178].  
 
The results of the experimental design were analyzed by JMP Pro 14 (Figure 3-4c). The 
independent variables and their interactions were evaluated using regression analysis. The 
significance of each term (factor and interaction) was determined by the F-test at a statistical level 
p <0.05. From Figure 3-4c, when excluding positive and negative control, there was no significant 
term except incubation time, indicating only incubation time influenced the transfection efficiency. 
Compared to the negative control (PBS), the groups of EVs did not show significantly higher 
lum/total protein in both 24 and 48 h incubation. The significance levels of other factors (DNA 
transfected into cells, type of carriers and total EV protein) and their interactions were greater than 
0.05 (Figure 3-4c), which means that those terms were not significantly affect the luciferase gene 
expression. 
 
Compared to untreated cells, Luc pDNA - containing MVs and EXOs could not increase luciferase 
gene expression neither at 24 h incubation nor at 48 h incubation. The slow transfection process 
of EV-mediated pDNA delivery was reported by Kanada and coworkers, and they hypothesized 
that the nucleic acid cargos delivered via EXOs and MVs were entrapped inside endosomes [118]. 
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Figure 3-4 Luciferase gene expression of EVs-mediated delivery of Luc pDNA. Blue bar 
represents EXOs, red bar represents MVs, orange bar represents negative control, control (PBS) 
and purple bar represents positive control, control (Lipo 3000, 10 ng). a) The influence of 
incubation time on gene expression. The hCMEC/D3 cells were transfected by positive control, 
negative control and luc pDNA – containing EXOs and MVs (from left to right). b) Luc pDNA 
loading in EXOs and MVs derived from transfected cells, which the transfected cells were treated 
by lipofectamine 3000/Luc pDNA with 0, 0.5, 1 µg/well (from left to right). c) Effect Tests showed 
the significance of each independent variables on luciferase gene expression. compared to other 
groups. Data is presented as mean ± SE of three independent experiments (n=3/experiment). 
Statistical comparisons were made using multiple regression analysis (# P < 0.05, compared to 
other groups). 
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3.3.4.  The change of cellular ATP levels in hCMEC/D3 cell line after treatment of MVs 
and EXOs 
 
Several papers reported that MVs packaged mitochondria and mitochondrial DNA (mtDNA) for 
cellular transfer [115, 116]. The western blot image confirmed the presence of mitochondrial 
marker in MVs. The major biological role of mitochondria is to produce ATP and support the 
energy requirements of cells. Mitochondria was reported to rescue anaerobic respiration and 
increase intracellular ATP level [116, 179].  In this section, we examined the effect of EXOs, MVs 
or MVs + EXOs in increasing cellular ATP levels in receptor hCMEC/D3 cells. Literatures 
reported that MVs and EXOs had different biogenesis and contained different protein and gene 
materials [100, 115], thus a combination of MVs and EXOs might include proteins and nucleic 
acids came from different biogenesis and result in higher cellular ATP level than MVs or EXOs 
alone. BDNF is an essential neurotrophin that can enhance the survival of neuronal cells and reduce 
cell death [58]. Thus, we transfected BDNF pDNA into the receptor cells via EXOs and MVs and 
investigated if BDNF pDNA could improve cell viability, compared to plain EXOs and MVs.  
 
The effect of each term (three factors and three interactions) on the cellular ATP levels were 
analyzed by JMP Pro 14 and are shown in Figure 3-5b and c. After 24 h incubation of EXOs and 
MVs with receptor hCMEC/D3, the p-value of type of carriers, total EV protein and DNA 
transfected into cells was smaller than 0.05, indicating that the three factors had significant effect 
on cellular ATP levels. Especially, the type of carriers had the lowest p-value, suggesting that the 
type of carriers was the most important term. At 48 h incubation, the type of carriers and amount 
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of DNA transfected into the parent cells showed significant effect. The three interactions did not 
significantly affect the cellular ATP level. 
 
The change in cellular ATP levels in receptor hCMEC/D3 cells after treatment of BDNF pDNA-
containing MVs and EXOs is shown in Figure 3-5a and c. The relative ATP levels for all groups 
were higher than 100% (solid black line in Figure 3-5a and c), which indicated that all treatments 
resulted in an increase in cellular ATP level. At 24 h incubation (Figure 3-5a), when total EV 
protein (either 6 µg or 12 µg) and BDNF transfected into cells (0, 0.5 or 1 µg/well BDNF pDNA) 
were fixed, the EXOs group had the highest amount of relative ATP level, followed MVs and then 
MVs + EXOs. It indicated that EXOs increased cell proliferation at normoxic condition (complete 
D3 growth medium, 72% N2 + 21% O2 + 5% CO2) to a great extent than MVs and MVs + EXOs. 
Moreover, when keeping the type of carriers and total EV protein constant, the EXOs or MVs 
extracted from cells which were transfected with higher dose of BDNF pDNA resulted in relatively 
lower ATP levels. This result revealed that the EVs without BDNF pDNA (plain EVs) improved 
cell proliferation more than the EVs with BDNF pDNA. Besides, comparing the outcome of 6 µg 
and 12 µg of total EV protein with fixed type of carriers and BDNF pDNA transfected into cells, 
6 µg of total EV protein resulted in a higher relative ATP level than 12 µg. The similar result was 
observed at 48 h incubation as well (Figure 3-5c). 
 
Many papers reported that MVs contained mitochondria, and delivery of mitochondria resulted 
increase in intracellular ATP level [115, 116, 179]. We confirmed the existence of mitochondrial 
marker in the MVs. However, our result showed that EXOs resulted in higher cellular ATP levels 
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than MVs and MVs + EXOs. Compared to EXOs which contained exosomal proteins and nucleic 
acids, the extra mitochondria in MVs might not increase cell proliferation at normoxic condition. 
Based on the experimental results, the group that maximize the cellular ATP levels was the plain 
EXOs with low total EV protein (6 µg). It contradicted our expectation. Typically, growth proteins 
such as vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) supplied 
by EVs advances cell proliferation. But the data showed 12 µg total EV protein lead to a lower 
relative ATP level than 6 µg, indicating that the levels of cell proliferation at the high dose EVs is 
not as good as the low dose. In another words, there probably exist an optimal dose of EVs that 
improve cell proliferation the most efficiently. The EVs from BDNF pDNA-transfected cells had 
statistically significant (p < 0.05) lower effect on the improvement of cell proliferation than the 
EVs from non-DNA transfected cells at both 24 h and 48 h. A possible reason is that the BDNF 
pDNA and residual lipofection materials replaced the part of original functional protein and gene 
materials in the EVs and thus reduced their biological activity. The underlying reason for pure 
EXOs being better than the combination of EXOs and MVs remains unclear. Since the dose of 
EVs and cell performance did not have a simple linear correlation, the authors hypothesized the 
influence of EXOs and MVs on cell proliferation were not a simple additive but a complex and 
interactive effect. 
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Figure 3-5 The change of relative ATP level after treatment of EVs in 24- and 48-hours’ incubation. 
a) and c) The influence of type of carriers, BDNF pDNA transfected into cells, and total EV protein 
on the relative ATP level. The hCMEC/D3 cells were incubated with EXOs and MVs contained 
different amount of BDNF pDNA at two levels of total EV’s protein (6 µg or 12 µg) at 24 hours 
or 48 hours (from left to right). b) and d) Effect Tests showed the significance of each term on the 
relative ATP level at 24 hours or 48 hours. The solid black line (−) at 100% represents that the 
mean luminescence of cells treated with EVs was normalized to the mean luminescence of 
untreated cells (negative control). Data is presented as mean ± SE of three independent 
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experiments (n=6/experiment). Statistical comparisons were made using multiple regression 
analysis (# P < 0.05, * P < 0.0001 compared to other groups). 
 
3.4.  Conclusion 
 
In this study, standard isolation procedures were applied to extract EXOs and MVs from the 
supernatant of donor hCMEC/D3 cells. EVs were characterized for their particle size, zeta 
potential and molecular markers. The EXOs and MVs were and structurally distinct from each 
other. The EXOs had relatively smaller size and more homogenous population than MVs. Due to 
the overlap of the size distribution of EXOs and MVs, the size alone did not distinguish EVs from 
one another. Western blot was applied as a second method to examine the exosomal and MV 
markers. We confirmed the presence of exosomal markers (CD9 and Alix) in EXOs. Although we 
did not find the GRP94 in the MVs, the mitochondrial marker (ATP5A) was showed in the western 
blot image. Both MVs and EXOs contained DNA. Meanwhile, the DNA contained in EVs did not 
lead to the excessive luciferase gene expression. The ATP assay demonstrated that, for healthy 
cells, plain EXOs and low total EV protein was the group that improved cell proliferation the most. 
In conclusion, our data confirmed that EXOs and MVs increased cellular ATP levels. This result 
might give some indications for future application of EVs in the treatment of cells under oxygen-
glucose deprivation (OGD) condition. Under stroke conditions, the brain cells suffer oxygen and 
nutrient deficits. The EXOs and MVs, which contained extra mitochondria and functional proteins 
and nucleic acids may serve as a regenerative therapy to provide nutrients and energy for injured 
cells and increase the rate of cell survival. 
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